levodopa has been researched along with benserazide in 682 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 293 (42.96) | 18.7374 |
| 1990's | 144 (21.11) | 18.2507 |
| 2000's | 103 (15.10) | 29.6817 |
| 2010's | 123 (18.04) | 24.3611 |
| 2020's | 19 (2.79) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A; Tam, KY | 1 |
| Bajpai, M; Banerjee, A; Bhateja, DK; Gandhi, MN; Gharat, LA; Gudi, GS; Gullapalli, S; Gupta, PK; Khairatkar-Joshi, N; Patil, S; Pawar, MY; Sangana, RR | 1 |
| Gerlach, J; Lühdorf, K | 1 |
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Rinne, UK | 2 |
| Tyce, GM; Wong, KL | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Hyyppä, M; Marttila, R; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rinne, UK | 1 |
| Ambrozi, L; Birkmayer, W; Riederer, P; Youdim, MB | 1 |
| Coxon, A; Greenacre, JK; Petrie, A; Reid, JL | 1 |
| Crossman, AR; Sambrook, MA; Slater, P | 1 |
| Falck, B; Hardebo, JE; Owman, C | 1 |
| Bailey, RC; Bracs, PU; Jackson, DM | 1 |
| Belliard, JP; Boismare, F; Hacpille, L; Le Poncin, M | 2 |
| Benkert, O | 1 |
| Yahr, MD | 2 |
| Darwish, SA; Furman, BL | 1 |
| Jahodová, J; Pribyl, T; Schreiber, V | 1 |
| Ljungberg, T; Ungerstedt, U | 1 |
| Dinnendahl, V; Gumulka, SW; Peters, HD; Schönhöfer, PS | 1 |
| Carolei, A; Margotta, V; Palladini, G | 1 |
| Myslinski, NR; Thut, PD | 1 |
| Snodgrass, SR; Uretsky, NJ | 1 |
| Pohto, P | 1 |
| Hiestand, PC | 1 |
| Barbeau, A; Butterworth, RF; Campanella, G; Yamada, K | 1 |
| Borri, P; Borri-Voltattorni, C; Minelli, A | 1 |
| Harvey, JA; Schlosberg, AJ | 1 |
| Hjälmås, K; Rubenson, A; Sillén, U | 1 |
| Gilland, O | 1 |
| Castegnaro, E; Pontiroli, AE; Pozza, G; Vettaro, MP; Viberti, GC | 1 |
| Battistin, L; Meneghetti, G; Rigotti, S; Saia, A | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 1 |
| Halvorsen, KA; Martensen-Larsen, O | 1 |
| van Rossum, JM | 1 |
| Carlyle, D; Williams, BO | 1 |
| Del Pesce, M; Di Bella, P; Forastieri, L; Paggi, A; Quattrini, A | 1 |
| Enström, MS; Liedén, G; Linström, FD | 1 |
| Martin, S | 1 |
| Chia, YC; Lees, GJ; Waterhouse, MJ | 1 |
| Hirayama, K; Kondo, T; Kuruma, I; Narabayashi, H; Yokochi, M | 2 |
| Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P | 1 |
| Bender, DA; Earl, CJ; Lees, AJ | 1 |
| Barrionuevo, JA; Cabezas-Cerrato, J; Casanueva, F; Peñalva, A; Vila, T; Villanueva, L | 1 |
| Cassi, E; Massarotti, G; Passaleva, A | 1 |
| Dadkar, VN; Dahanukar, SA; Sheth, UK | 1 |
| Conte, P; Julien, J; Moulinier, J; Reiffers, J | 1 |
| Adlmici, G; Callea, L; Di Monda, V; Fazzari, G | 1 |
| Fernstrom, JD; Wiggins, JF | 1 |
| Duvoisin, RC; Mytilineou, C | 1 |
| Uemura, H | 1 |
| Mölsä, P; Rinne, UK | 1 |
| Caraceni, TA; Celano, I; Girotti, F; Parati, E | 1 |
| Ho, YM; Shau-Fong, K | 1 |
| Boismare, F; Boquet, J; Le Poncin, M; Lefrançois, J | 1 |
| Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M | 2 |
| Buckley, JP; Lokhandwala, MF | 1 |
| Wick, MM | 1 |
| Gorman, M; Kramer, RA; Wick, MM | 1 |
| Gessa, GL; Mereu, G; Paglietti, E; Quarantotti, BP | 1 |
| Gallamini, A; Magnani, G; Masturzo, P; Murialdo, G; Nizzo, MC | 1 |
| Marttila, R; Rinne, UK | 1 |
| Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R | 1 |
| Kuzuya, F; Mori, K; Sakamoto, N; Yoshimine, N | 1 |
| Birkmayer, W | 2 |
| Rinne, UK; Siirtola, T; Sonninen, V | 2 |
| Lazarova, MB; Roussinov, KS | 1 |
| Collins, MA; Hannigan, JJ; Weiner, C | 1 |
| Clemens, R | 1 |
| Bartholini, G; Pletscher, A | 1 |
| Ernst, AM | 1 |
| Gerlach, J | 1 |
| Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM | 1 |
| Bissessur, S; De Man, JJ; Lakke, JP; Moll, L; Seegers, J; Wesseling, H; Witt, FG | 1 |
| Faure, A | 1 |
| Chouza, C; Gomensoro, JB; Romero, S | 4 |
| Markianos, ES; Rüther, E | 1 |
| Carolei, A; Casacchi, M; Fazio, C | 1 |
| Herishanu, Y; Rosenberg, P | 1 |
| Slome, R | 1 |
| Algeri, S; Campanella, G; Cerletti, C; Dolfini, E; Jori, A; Rinaldi, F | 1 |
| Bartolini, A; Mantovani, P; Pepeu, G | 1 |
| Messiha, FS | 2 |
| Thut, PD | 1 |
| Agid, Y; Lhermitte, F; Signoret, JL; Studler, JM | 1 |
| Kisara, K; Shoji, T; Tadano, T | 1 |
| Rolls, ET; Shaw, SG | 1 |
| Barbeau, A; Roy, M | 1 |
| Siegfried, J; Zumstein, H | 1 |
| Boismare, F; Hacpille, L; Le Poncin, M | 1 |
| Goodwin, BL; Johnson, RD; Ruthven, CR; Sandler, M | 1 |
| Bass-Verrey, F; Ludin, HP | 1 |
| Goodale, DB; Moore, KE | 1 |
| Anggård, E; Samuelsson, K | 1 |
| Augier, D; Dutau, G; Enjaume, P; Ribot, C; Rochiccioli, P | 1 |
| Mizuno, Y; Obayashi, T; Ueki, A; Yoshida, M | 1 |
| Cooper, RL; Linnoila, M | 1 |
| Lapin, IP; Patkina, NA | 1 |
| Tyce, GM | 1 |
| Burlet, DB | 1 |
| Gräf, HJ; Horowski, R | 1 |
| Kato, N; Murase, Y | 1 |
| Garncarczyk, L; Maj, J; Mogilnicka, E; Pawlowski, L | 1 |
| Harrisson, F | 1 |
| Gabreëls, FJ; Joosten, EM; Keyser, A; Korten, JJ | 1 |
| Bathien, N; Dumas, JL; Rondot, P | 1 |
| Eplov, L; Nielsen, M; Scheel-Krüger, J | 2 |
| Fernandez, FC; Lindsley, DF; Ranf, SK; Wyrwicka, W | 1 |
| Boismare, F; Boquet, J | 1 |
| Barbeau, A | 1 |
| Birket-Smith, E | 1 |
| Barbeau, A; Inoue, N; Tsukada, Y | 1 |
| Kuschinsky, K | 1 |
| Geller, I; Messiha, FS; Morgan, M | 1 |
| Maj, J; Przewlocka, B | 1 |
| Aldor, T; Gilat, T; Kesten, M; Loewenthal, M; Streifler, M | 1 |
| Antonaccio, MJ; Kerwin, L | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK | 1 |
| Miller, S; van der Meché, FG | 1 |
| Barsegian, GG; Butenko, OB; Kordzadze, RN | 1 |
| Bruyland, M; De Keyser, J; Ebinger, G; Herroelen, L; Vervaeck, M | 1 |
| Kraus, PH; Letzel, H; Przuntek, H; Schwarzmann, D; Welzel, D | 1 |
| Coper, H; Hausmanowa-Petrusewicz, I; Kaminska, A; Ossowska, K; Schulze, G; Wolfarth, S | 1 |
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Furukawa, Y; Kondo, T; Mizuno, Y; Narabayashi, H; Nishi, K | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Chen, S | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| Acquas, E; Carboni, E; Da Prada, M; de Ree, RH; Di Chiara, G | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Lauerma, H | 1 |
| Barbanel, G; Kamenka, JM; Maurice, T; Vignon, J | 1 |
| Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D | 1 |
| Jacquot, C; Maubrey, MC; Raynal, H; Trouvin, JH | 1 |
| Agren, H; Bjurling, P; Hartvig, P; Kihlberg, T; Långström, B; Reibring, L; Tedroff, J | 1 |
| Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW | 1 |
| Ariano, MA; Chase, TN; Engber, TM; Susel, Z | 1 |
| Chaná, P; Díaz, F | 1 |
| Andersson, Y; Antoni, G; Bjurling, P; Hartvig, P; Långström, B; Tedroff, J | 1 |
| Da Prada, M | 1 |
| Lundquist, I; Panagiotidis, G; Stenström, A | 1 |
| Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H | 1 |
| Bartholomé, K; Görke, W | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Kempi, V; von Scheele, C | 1 |
| Nagatsu, T; Niwa, T; Yoshida, M | 1 |
| Graham, JS; Henderson, JM; Morris, JG; Yiannikas, C | 1 |
| Cunningham, MA; Darby, DG; Donnan, GA | 1 |
| Geffard, M; Henry, P; Mons, N; Tison, F | 1 |
| Agnoli, A; Carta, A; Marsden, CD; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Colzi, A; Da Prada, M; Zürcher, G | 1 |
| Bondarenko, NA; Kudrin, VS; Miroshnichenko, II; Rayevsky, KS | 1 |
| Kent, AP; Stern, GM; Webster, RA | 1 |
| Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A | 1 |
| Edwards, RL; Oliver, WA; Todman, DH | 1 |
| Carboni, S; Gessa, GL; Pani, L; Portas, CM; Rossetti, ZL | 1 |
| Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H | 1 |
| Blackburn, NA; Boddie, HG; Ellis, CJ; Kendal, BR; MacMahon, DG; Sachdev, D | 1 |
| Pletscher, A | 1 |
| Lees, AJ | 3 |
| Jansen, EN; Meerwaldtt, JD | 1 |
| Covicković-Sternić, N; Kostić, VS | 1 |
| Aissi, E; Delorme, P; Hevor, TK | 1 |
| Bruggi, P; Martignoni, E; Nappi, G; Pacchetti, C; Sibilla, L; Turla, M | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Gottlob, I; Stangler-Zuschrott, E | 1 |
| Allievi, C; Bellotti, V; Benedetti, MS; Dordain, G; Dostert, P | 1 |
| Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V | 1 |
| Kraus, P; Kuhn, W; Przuntek, H | 1 |
| Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A | 1 |
| Rammsayer, T | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Dordain, G; Dostert, P; Strolin Benedetti, M; Vernay, D | 1 |
| Campanella, G; De Michele, G; Filla, A; Mengano, A; Trombetta, L | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| d'Anglejan Chatillon, J | 1 |
| Emskötter, T; Heidenreich, C; Lachenmayer, L | 1 |
| Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Allain, H; Bentue-Ferrer, D; Defawe, G; Jacquemard, F; Milon, D; Moran, P | 1 |
| Boomsma, F; Hovestadt, A; Man in't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Liu, DK | 3 |
| Caraceni, T; Lamperti, E; Lorizio, A; Nordera, N | 1 |
| Dichgans, J; Scholz, E | 1 |
| Cohen, Y; el Gemayel, G; Jacquot, C; Prioux-Guyonneau, M; Trouvin, JH | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| von Scheele, C | 1 |
| Hardie, RJ; Lees, AJ | 1 |
| Albani, C; Hacisalihzade, SS; Mansour, M | 1 |
| Black, MJ; Brandt, RB | 1 |
| Cossutta, E; Ferrante, C; Pezzoli, G; Scarlato, G; Tesei, S; Zecchinelli, A | 2 |
| Bhattacharya, SK; Parmar, SS | 1 |
| Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A | 1 |
| Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO | 2 |
| Brodeur, C; Godbout, R; Marinier, R; Montplaisir, J | 1 |
| Ketsche, R; Vogel, HP | 1 |
| Stern, G | 1 |
| Mondal, BK; Mondal, KN | 1 |
| Birkmayer, GD; Birkmayer, W | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Lindström, P; Ohlsson, L | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Da Prada, M; Haefely, WE; Kettler, R; Schaffner, R; Zürcher, G | 1 |
| Kuhn, W; Przuntek, H | 1 |
| Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS | 1 |
| Battegay, R; Gastpar, M; Zmilacher, K | 1 |
| Bliesath, H; Jellinger, K | 1 |
| Marion, MH; Marsden, CD; Quinn, NP | 1 |
| Aymard, N; Holzer, J; Rondot, P; Ziegler, M | 2 |
| Erni, W; Held, K | 1 |
| Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 1 |
| Ludin, HP | 2 |
| D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP | 1 |
| Baas, H; Fischer, PA | 1 |
| Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J | 1 |
| Lees, AJ; Poewe, WH; Stern, GM | 1 |
| Grundmann, M; Schimrigk, K | 1 |
| Jansen, EN; Meerwaldt, JD | 1 |
| Wermuth, L | 1 |
| Bondarenko, NA; Kudrin, VS; Miroshnichenko, II | 1 |
| Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP | 1 |
| Crevoisier, C; Da Prada, M; Hoevels, B; Zürcher, G | 1 |
| Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A | 1 |
| Siegfried, J | 1 |
| Bédard, PJ; Dipaolo, T; Falardeau, P; Rouillard, C | 1 |
| Bhakthavatsalam, P; Ghosh, MN; Kamatchi, GL | 1 |
| Lieberman, AN | 1 |
| Dupont, E; Jakobsen, J; Mikkelsen, B | 1 |
| Akpinar, S | 2 |
| Jenner, P; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 1 |
| De Jesus, OT; Dinerstein, RJ; Friedman, AM; Van Moffaert, GJ | 1 |
| Wilson, JA | 1 |
| Langdon, N; Malcolm, PN; Parkes, JD | 1 |
| Corsi-Cabrera, M; Galarraga, E; Sangri, M | 1 |
| Albani, C; Asper, R; Baumgartner, G; Hacisalihzade, SS | 1 |
| Aizenstein, ML; de-Lucia, R; Scavone, C; Steinschreiber, S | 1 |
| Farel, PB; McClellan, AD | 1 |
| Kapfhammer, HP; Kuss, HJ; Rüther, E | 1 |
| Close, SP; Marriott, AS; Pay, S | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Birkmayer, W; Hars, V; Knoll, J; Marton, J; Riederer, P; Youdim, MB | 1 |
| Berglund, B; Kaijser, L; Sachs, C | 1 |
| Gillman, MA; Sandyk, R | 1 |
| Agid, Y; Bonnet, AM; Esteguy, M; Kefalos, J; Lhermitte, F | 1 |
| Admani, AK; Cordingley, GJ; Harris, RI; Verma, S | 1 |
| Domenici, L; Fiorentini, A; Maffei, L; Piccolino, M; Trimarchi, C | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Jyoichi, T; Kobayashi, M; Miyahara, T; Ogura, Y; Sato, S; Shimojyo, S; Yasuda, K | 1 |
| Bartholini, G; Keller, HH; Pletscher, A | 1 |
| Rondot, P | 1 |
| Davis, HN; Dewsbury, DA; Gray, GD | 1 |
| Antonaccio, MJ; Burrell, R; Robson, RD | 1 |
| Jancsó, G | 1 |
| Balestreri, R; Bertolini, S; Costa, S; Elicio, N | 1 |
| Fischer, PA; Gundelsheimer, W; Jacobi, P; Schneider, E | 1 |
| Baumann, N; Castaigne, P; Rondot, P; Taberlet, A | 1 |
| Campanella, G; Pennetta, R | 1 |
| Masi, G; Megna, GF; Puca, FM; Specchio, LM | 1 |
| Steinhäusl, H | 1 |
| De Mattei, M; Gentile, S; Pinessi, L; Sabbatini, F | 1 |
| Bjørndal, N; Casey, D; Gerlach, J | 1 |
| Daniele, E; Zamboni, P | 1 |
| Henning, M; Johansson, P | 2 |
| Rogóz, Z; Skuza, G; Sowińska, H | 2 |
| Alsasua, A; Arias, J; Arias, JI; Durán Sacristan, H; Durán, M; Estebánez, E; Garciá de Jalón, PD; López Sánchez, ML | 1 |
| Bjørndal, N; Casey, DE; Gerlach, J | 1 |
| Jackson, DM; Miller, LP; Walters, JR | 1 |
| Baker, H; Joh, TH; Kawano, T; Margolis, FL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Achilli, G; Algeri, S; Cimino, M; Lipartiti, M; Perego, C; Ponzio, F; Vantini, G | 1 |
| Coulon, JF; David, JC; Lafon-Cazal, M | 1 |
| Cairns, MJ; Foldys, JE; Rees, JM | 1 |
| Gross, G; Krause, KH; Nagel-Hiemke, M | 1 |
| Kohno, Y | 1 |
| Watanabe, Y | 1 |
| Ahlenius, S; Svensson, L | 1 |
| van der Zee, HJ; van Nieuwenhuizen, O; Zweije-Hofman, IL | 1 |
| Fischer, PA; Majer, M; Przuntek, H; Welzel, D | 1 |
| Iadgarov, IS; Kandel', EI | 1 |
| Baraczka, K; Fekete, MI; Kanyicska, B | 1 |
| Bihari, K; Fekete, M; Katona, G; Tárczy, M | 1 |
| Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Csanda, E; Tárczy, M | 1 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Kuroda, H; Nukina, I; Ogawa, N; Ota, Z; Yamamoto, M | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Parati, EA; Zanardi, P | 1 |
| Bondiolotti, GP; Cocchi, D; Locatelli, V; Müller, EE; Parati, EA; Parenti, M; Penalva, A; Picotti, GB | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Hori, A; Kariya, T; Nakagawara, M; Watanabe, A | 1 |
| Rondot, P; Ziegler, M | 1 |
| Da Prada, M; Gundert-Remy, U; Hildebrandt, R; Stiehl, A; Weber, E; Zürcher, G | 1 |
| Baldassarre, G; Fazio, B | 1 |
| Schiffter, R; Vogel, HP | 1 |
| Christie, MJ; Gregory, P; Jackson, DM; Jenkins, OF; Malor, R | 1 |
| Gerdes, U; Lehmann, K; Ulm, G | 1 |
| Cartlidge, NE; Gibson, GJ; Gilmartin, JJ; Wright, AJ | 1 |
| Kamenetskiĭ, VK | 1 |
| Lindstöm, P | 1 |
| Bailey, R; Crisp, E; Jackson, DM; Jenkins, O | 2 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Marttila, R; Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Alaghband-Zadeh, J; Das, PK; Gawel, MJ; Lavin, PJ; Rose, FC | 1 |
| Dean, BC; McLellan, DL | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Ando, K | 1 |
| Hauchecorne, J; Kernbaum, S | 1 |
| Klingler, M | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Keren, O; Korczyn, AD | 1 |
| Passerini, D; Pezzoli, G; Radaelli, F; Scarlato, G | 1 |
| Callingham, BA; Lyles, GA | 2 |
| Hildick-Smith, M | 1 |
| Johansson, P | 1 |
| Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S | 1 |
| Brouwer, GM; Hanstede, JG; Mattheij, JA; Swarts, JJ | 1 |
| Riederer, P | 1 |
| Chan, LL; Sinniah, D | 1 |
| Caraceni, T; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A; Parati, E | 1 |
| Boomsma, F; Man in 't Veld, A; Schalekamp, M; van den Meiracker, A | 1 |
| Casas Parera, I; Diaz, S; Fernández Pardal, MM; Gatto, E; Micheli, F | 1 |
| Dessibourg, CA; Gachoud, JP | 1 |
| Dovedova, EL; Gershteĭn, LM | 1 |
| Mamalyga, LM; Meerson, FZ | 1 |
| Channon, S; Lees, AJ; Ramponi, C; Sieradzan, K; Stern, GM; Youdim, MB | 1 |
| Clinnick, S; Fonda, D; Schwarz, J | 1 |
| Elias, MM; Levin, G; Nowicki, S; Ochoa, EJ | 1 |
| Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N | 1 |
| Chen, CF; Hsieh, CC; Hsieh, MT; Peng, WH; Su, SH; Tsai, HY | 1 |
| Da Prada, M; Napolitano, A; Zürcher, G | 1 |
| Pestana, M; Soares-da-Silva, P | 1 |
| Gershteĭn, LM; Kukuev, LA; Sergutina, AV | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| De Klippel, N; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Khalil, R; Milandre, L | 1 |
| Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T | 1 |
| Himori, N; Mishima, K | 1 |
| Baas, H; Bergemann, N; Fischer, PA | 1 |
| Duché, B; Loiseau, P; Tison, F | 1 |
| Albani, C; Bächli, E | 1 |
| Kanda, T; Nakamura, J; Shimada, J; Shiozaki, S; Suzuki, F | 1 |
| González, J; Masana, L; Olivé, JM | 1 |
| Dichgans, J; Klockgether, T | 1 |
| Araújo, Ade Q; Miranda, SB | 1 |
| Asari, S; Date, I; Furuta, T; Imaoka, T; Miyoshi, Y; Ohmoto, T; Yoshimoto, Y | 1 |
| Akaike, N; Himori, N; Kurasawa, M; Mishima, K; Tanaka, Y | 1 |
| Grandjean, P | 1 |
| Helscher, RJ; Pinter, MM | 1 |
| Cheng, FC; Chia, LG; Kuo, JS | 1 |
| Atchison, PR; Frackowiak, RS; Marsden, CD; Thompson, PD | 1 |
| Chanter, DO | 1 |
| Albani, C; Buck, A | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Da Prada, M; Dingemanse, J; Zürcher, G | 1 |
| Enero, MA; Levin, G; Nowicki, S | 1 |
| Ahrenstedt, O; Aquilonius, SM; Knutson, L; Lennernäs, H; Nilsson, D; Paalzow, LK | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Amiel, C; Comoy, E; Couette, S; Friedlander, G; Garcia-Ocaña, A; Perrichot, R | 1 |
| Gorchein, A | 1 |
| Kazenwadel, J; Kohnen, R; Krüger, HP; Künzel, M; Pollmächer, T; Ramm, S; Schwarz, J; Stiasny, K; Trenkwalder, C; Wetter, T | 1 |
| Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C | 1 |
| Byth, K; Einstein, R; Henderson, JM; Jackson, DM; Morris, JG | 1 |
| Bayülkem, B; Bayülkem, K; Erişir, K; Tuncel, A | 1 |
| Dubuis, R; Limousin, P; Perret, JE; Pfefen, JP; Pollak, P; Tournier-Gervason, CL | 1 |
| Chen, CF; Ho, YF; Hsieh, MT; Peng, WH; Wu, CR | 1 |
| Kaur, S; Starr, M | 1 |
| Ashby, CR; Emori, K; Minabe, Y | 1 |
| Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J | 1 |
| Ichikawa, M; Matsuyama, K; Nakashima, M; Nakashima, MN; Sakurai, M; Sasaki, H; Zhao, MF | 1 |
| Ghi, P; Molinengo, L; Orsetti, M; Pastorello, B; Scordo, I | 1 |
| Brenci, S; Indiveri, F; Lotti, G; Musso, NR; Setti, M | 1 |
| Kammer, T; Kischka, U; Maier, S; Spitzer, M; Thimm, M; Weisbrod, M | 1 |
| Achilli, G; Banting, A; Banting, S; Le Bars, D; Weil-Fugazza, J | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Lavigne, GJ; Lobbezoo, F; Montplaisir, JY; Tanguay, R | 1 |
| Shan, DE; Yeh, SI | 1 |
| Gachoud, JP; Gasser, U; Ghika, J | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Chang, WY; Webster, RA | 1 |
| Hanihara, T; Inoue, K; Iwabuchi, K; Kawanishi, C; Kosaka, K; Miyakawa, T; Onishi, H; Osaka, H; Owada, M; Sugiyama, N; Yamada, Y | 1 |
| Soares-da-Silva, P; Vieira-Coelho, MA | 3 |
| Gao, L; Han, W; Pu, L; Shao, C; Sun, Y; Yang, H; Zhang, Y | 1 |
| Chiang, JH; Fuh, JL; Lee, RC; Lin, CH; Liu, HC; Wang, PN; Wang, SJ | 1 |
| Arai, H; Hattori, T; Shinotoh, H | 1 |
| Crevoisier, C; Dingemanse, J; Kleinbloesem, CH; Wood, ND; Zürcher, G | 1 |
| Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Schmitt, M; Zürcher, G | 1 |
| Byth, K; Einstein, R; Henderson, JM; Jackson, D; Morris, JG; Yiannikas, C | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Häcker, R; Huston, JP; Mattern, C; Schwarting, RK; Silva, MA; Tomaz, C | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Pestana, M; Serrão, MP; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Serrão, MP; Soares-Da-Silva, P; Vieira-Coelho, MA | 1 |
| Barone, P; DiChiara, G; Morelli, M; Pellecchia, MT; Vallone, D; Verde, P | 1 |
| Leiva, C | 1 |
| Myers, CS; Wagner, GC; Witten, M; Yu, YL | 1 |
| Arac, N; Ertas, M; Ertekin, C; Sagduyu, A; Uludag, B | 1 |
| Goetz, CG | 1 |
| Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G | 1 |
| Honey, CR; Shen, H | 1 |
| Baas, H; Harder, S | 1 |
| Crevoisier, C; Dingemanse, J; Gasser, UE; Lankhaar, G; Ouwerkerk, M | 1 |
| Duka, T; Lupp, A | 1 |
| Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M | 1 |
| Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL | 1 |
| Prevett, MC; Rossor, MN | 1 |
| Halladay, AK; Myers, CS; Wagner, GC; Widmer, DA | 1 |
| de Mello, MT; Poyares, DL; Tufik, S | 1 |
| Dizdar, N; Granérus, AK; Hannestad, U; Kågedal, B; Kullman, A; Ljungdahl, A; Olsson, JE | 1 |
| Adams, AC; Keefe, KA | 1 |
| Kikuchi, K; Nishino, K; Ohyu, H | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Bangassoro, E; Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Hirschelmann, R; Thong, NT | 1 |
| Fanali, S; Pucci, V; Raggi, MA; Sabbioni, C | 1 |
| Barbarino-Monnier, P; Denis, E; Lurel, S; Routiot, T | 1 |
| Discalzi, G; Herrero Hernandez, E; Meliga, F; Pira, E; Turbiglio, M; Valentini, C | 1 |
| Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J | 1 |
| Golubev, VL; Sadekov, RA; Vendrova, MI | 1 |
| Brüne, M; Gerlach, G; Schröder, SG | 1 |
| Agid, Y; Arnulf, I; Bareille, MP; Bonnet, AM; Descombes, S; Dingemanse, J; Gasser, UE; Rascol, O; Thalamas, C | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Bacheschi, LA; Barbosa, ER; Leiros da Costa, MD; Leite, CC; Scaff, M | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Bartholomé, B; Bartholomé, K; Blau, N; Bonafé, L; Skrygan, M | 1 |
| Grange, S; Guentert, TW; Holford, NH | 1 |
| Benz, S; Börnke, C; Müller, T | 1 |
| Borri-Voltattorni, C; Burkhard, P; Dominici, P; Jansonius, JN; Malashkevich, VN | 1 |
| Boerman, RH; Hoefnagels, WH; Jansen, RW; Mehagnoul-Schipper, DJ | 1 |
| Canteras, NS; Da Cunha, C; Gevaerd, MS; Miyoshi, E; Silveira, R; Takahashi, RN | 1 |
| Hironishi, M; Kondo, T; Miwa, H | 1 |
| Blin, O; Hasbroucq, T; Micallef-Roll, J; Possamaï, CA; Rihet, P | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| de Rooij, SE; Jansen, PA; Moons, CG; Samson, MM; Verhaar, HJ | 1 |
| Fekete, MI; Fülöp, F; Homicskó, KG; Kertész, I; Nagy, GM; Radnai, B; Tóth, BE; Tóth, G | 1 |
| Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T | 1 |
| Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M | 1 |
| Einarson, TR; Iskedjian, M | 1 |
| Calvi-Gries, F; Crevoisier, C; Nilsen, T; Zerr, P | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M; Paganini, F; Stocchi, S | 1 |
| Andersson, M; Cenci, MA; Westin, JE | 1 |
| Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H | 1 |
| Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T | 1 |
| Anderer, P; Högl, B; Kunz, A; Poewe, W; Saletu, B; Saletu, M; Saletu-Zyhlarz, G | 1 |
| Gu, SD; Sun, XF; Wang, W; Zhao, DZ | 1 |
| Parada, A; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Li, Y; Tang, X | 1 |
| Almeida, L; Falcão, A; Loureiro, A; Machado, R; Maia, J; Silveira, P; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Collado Seidel, V; Kazenwadel, J; Kohnen, R; Oertel, W; Selzer, R; Trenkwalder, C; Wetter, TC | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R; Scaglione, C | 1 |
| Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K | 1 |
| Dziubina, A; Gołembiowska, K | 2 |
| Bonnet, JJ; Costentin, J; Lange, CM; Legros, H; Loutelier-Bourhis, C | 1 |
| Allard, M; Guyot, M; Sibon, I; Tison, F | 1 |
| Ehrenberg, BL; Eisensehr, I; Noachtar, S; Rogge Solti, S | 1 |
| Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D | 1 |
| Alam, M; Schmidt, WJ | 1 |
| Fukuda, T; Iwata, S; Masuyama, T; Morioka, H; Nomoto, M; Shimizu, T | 1 |
| Centurión, ME; Damiani, PC; Fernández Band, BS; Olivieri, AC; Pistonesi, M | 1 |
| Mühlau, G | 2 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Ardayfio, P; Chesselet, MF; Fleming, SM; Hwang, DY; Kim, H; Kim, KS; Moran-Gates, T; Tarazi, FI | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Mochi, M; Riva, R | 1 |
| Ianishevskiĭ, SN; Kovalenko, PA; Lobzin, SV; Odinak, MM; Vozniuk, IA | 1 |
| Gershteĭn, LM; Sergutina, AV | 1 |
| Bobkova, NV; Bondarenko, NA; Gudasheva, TA; Ostrovskaya, RU; Retyunskaya, MV; Samokhin, AN | 1 |
| Eltayb, A; Svensson, TH; Wadenberg, ML | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Karpińska, J; Smyk, J; Wołyniec, E | 1 |
| Cannas, A; Floris, G; Solla, P; Tacconi, P | 1 |
| Funabashi, T; Goshima, Y; Kimura, F; Kuroiwa, Y; Misu, Y; Shimamura, M; Shimizu, M; Yagami, T | 1 |
| Kohnen, R; Möller, JC; Oertel, WH; Stiasny-Kolster, K; Trenkwalder, C | 1 |
| Bourhis, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Muhlack, S; Müller, T; Welnic, J | 1 |
| He, WW; Lu, JQ; Zhou, XW | 1 |
| Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF | 1 |
| Cooper, JD; Davies, MI; Heppert, KE; Lunte, SM | 1 |
| Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H | 1 |
| Fukuda, T; Iwata, S; Miyata, A; Nomoto, M; Shimizu, T | 1 |
| Butzkueven, H; Evans, AH | 1 |
| Bliem, B; Dinse, HR; Frombach, E; Knossalla, F; Ragert, P; Tegenthoff, M; Woitalla, D | 1 |
| Jackson, MJ; Jenner, P; Katzenschlager, R; Lees, AJ; Rose, S; Smith, LA; Stockwell, K; Tayarani-Binazir, KA; Zubair, M | 1 |
| Baleanu, D; Dinç, E; Doganay, T; Kaya, S | 1 |
| Muhlack, S; Müller, T; Welnic, J; Woitalla, D | 1 |
| Chen, XH; Kui, Y; Li, Y | 1 |
| Buck, K; Ferger, B | 2 |
| Lian, XF; Luo, XD | 1 |
| Muhlack, S; Müller, T | 1 |
| Dupuis, M; Evrard, F; Jacquerye, P; Muller, T | 1 |
| Aghemo, A; Ballabio, E; Bersano, A; Candelise, L; Colombo, M; Rumi, MG | 1 |
| Chen, WJ; Lin, Y; Murong, SX; Wang, N; Wu, ZY; Xie, H; Zhao, GX | 1 |
| Adams, F; Boschmann, M; Franke, G; Gottschalk, S; Janke, J; Jordan, J; Kupsch, A; Leisse, MC; Lipp, A; Lobsien, E; Spranger, J | 1 |
| Lima, JL; Lopes, JA; Marques, KL; Santos, JL | 1 |
| Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Wang, J; Ye, Q; Yuan, CG; Yuan, CX; Zhang, Y | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Millan, MJ; Visanji, NP | 1 |
| Chan, P; Feng, T; Li, W; Lu, L; Shi, W; Wang, Y; Zhang, J | 1 |
| Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Ren, XM | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Karges, W; Schöfl, C; Tischendorf, JJ | 1 |
| Dziubina, A; Gołembiowska, K; Kamińska, K; Kowalska, M | 1 |
| García-Gutiérrez, MS; Ledent, C; Leiva, C; Leza, JC; Manzanares, J; Molina, JA; Pérez-Nievas, BG; Pérez-Rial, S | 1 |
| Itoh, S; Oo, C | 1 |
| Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ | 1 |
| Castellanos, FX; Copland, DA; de Zubicaray, G; Di Martino, A; Kelly, C; Klein, DF; McMahon, K; Milham, MP; Reiss, PT | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT | 1 |
| Hsu, CH; Wang, HB | 1 |
| Huang, Y; Jiang, X; Tang, A; Wik, G; Zhuo, Y | 1 |
| Almeida, L; Costa, R; Falcão, A; Fernandes-Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, JF; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Feinstein, DL; Galea, E; McGuire, S; Polak, PE; Sharp, A; Simonini, MV | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G | 1 |
| Fukumura, T; Hosoi, R; Inoue, O; Nakao, R; Okada, M; Suzuki, K; Zhang, MR | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Alvarez-Lueje, A; Bravo, M; Olivieri, AC; Pérez-Ortiz, M; Zapata-Urzúa, C | 1 |
| Kek, PC; Prakash, KM | 1 |
| Inoue, T; Koyama, M; Ogata, A; Tani, Y | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH | 1 |
| Dick, OE; Nozdrachev, AD; Romanov, SP | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Gershteĭn, LM; Rakhmanova, VI; Tatarintseva, IM | 1 |
| Hashim, HZ; Ibrahim, N; Ngiu, CS; Tan, HJ; Wan Musa, WR; Wan Yahya, WN | 1 |
| Assefi, AR; Bertuola, R; Czerniuk, P; Di Girolamo, G; Keller, GA; Spatz, JG | 1 |
| Egeland, M; Svenningsson, P; Zhang, X | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM | 1 |
| Geiser, E; Kaelin-Lang, A | 1 |
| Hormozi-Nezhad, MR; Khodaveisi, J; Tashkhourian, J | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Bonfim, RR; Byrro, RM; Cardoso, FF; César, Ida C; da Silva, EP; Gomes, SA; Mundim, IM; Pianetti, GA; Teixeira, Lde S | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Asada, M; Asada, N; Fehling, HJ; Fukatsu, A; Kimura, T; Kita, T; Minegishi, N; Nagoshi, N; Nakamura, J; Oguchi, A; Okano, H; Rao, TN; Shibata, S; Suzuki, N; Takase, M; Yamamoto, M; Yamamura, K; Yanagita, M | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Kuric, E; Ruscher, K; Wieloch, T | 1 |
| Bassetti, CL; Bornatico, F; Fuhr, P; Kallweit, U; Mathis, J; Schwander, J | 1 |
| Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J | 1 |
| Heekeren, K; Hitz, K; Huber, T; Juckel, G; Kawohl, W; Obermann, C | 1 |
| Bakheit, AM; Brennan, A; Fletcher, K | 1 |
| Jackson, MJ; Jairaj, M; Jenner, P; Rose, S; Strang, I; Tayarani-Binazir, KA | 1 |
| Li, M; Li, SD; Liu, Y; Yang, MH | 1 |
| Blau, N; Dill, P; Somerville, A; Thöny, B; Wagner, M; Weber, P | 1 |
| Adkins, CE; Cenci, MA; Lockman, PR; Lundblad, C; Ohlin, KE; Sebastianutto, I | 1 |
| Alcacer, C; Gaven, F; Girault, JA; Hervé, D; Santini, E; Valjent, E | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R | 1 |
| Munhoz, RP; Teive, HA; Zavala, JA | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Li, M; Liu, Y; Yang, MH | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Brasun, J; Kotynia, A; Malinka, W; Pap, JS; Szewczuk, Z; Szyrwiel, L | 1 |
| Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F | 1 |
| Arnet, I; Fischer, A; Gasser, UE; Timmermans, JP | 1 |
| Hodoba, D; Santic, AM; Schmidt, D | 1 |
| Ma, YZ; Shen, XM; Zhang, J | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC | 1 |
| Aquino, CC; Borges, V; Celso de Castro, P; Doná, F; Ferraz, HB; Medeiros, L; Silva, SM | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R | 1 |
| Bleickardt, C; Chitravanshi, VC; Cote, SR; Kuzhikandathil, EV; Sapru, HN | 1 |
| Dolan, RJ; McNab, F | 1 |
| Kuric, E; Ruscher, K | 3 |
| Hattori, N | 1 |
| Deng, M; Fang, Y; Huang, L; Li, L; Zhang, S | 1 |
| Adrien, J; Arnulf, I; Belaid, H; Clark, SD; Drouot, X; François, C; Grabli, D; Hirsch, EC; Karachi, C; Laffrat, E; Tandé, D | 1 |
| Du, L; Lei, F; Li, Y; Sun, Y; Tang, X; Yang, L | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 1 |
| Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Alirezaei, M; Dezfoulian, O; Khoshdel, Z; Rashidipour, M; Taghadosi, V | 1 |
| Abrams, MB; Galter, D; Gellhaar, S; Marcellino, D | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Baumann, CR; Epprecht, L; Goetze, O; Schreglmann, SR; Waldvogel, D; Woitalla, D | 1 |
| Bäckman, CM; Cadet, JL; Chiang, YH; Diaz, O; Hoffer, BJ; Ladenheim, B; Olson, L; Shan, L; Zhang, Y | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Cao, ZH; Chen, HX; Ding, ZG; Song, JH; Zhang, GB; Zhou, PY | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Chan, P; Feng, T; Hallett, M; Hou, Y; Wu, T; Zhang, J | 1 |
| Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P | 1 |
| Abe, H; Ebihara, K; Ikarashi, Y; Imamura, S; Ishida, Y; Kase, Y; Koganemaru, G; Mizoguchi, K; Sekiguchi, K; Tabuchi, M | 1 |
| Du, N; Guo, Z; Han, M; Huang, Y; Liu, J; Xu, S | 1 |
| Bang, JI; Jung, IS; Kim, SE; Lee, BC; Moon, BS; Park, HS; Song, YS | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Di Caudo, C; Gonzalez-Maldonado, R; Gonzalez-Redondo, R | 1 |
| Cao, LD; Guo, G; Wu, QY; Xu, S | 1 |
| Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X | 1 |
| Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E | 1 |
| Bugdol, M; Czernek, M; Derejczyk, J; Kapko, W; Kawa, J; Marcisz, C; Seiffert, P; Stępień-Wyrobiec, O; Szymszal, J; Torbus, A | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Contin, M; Isaias, IU; Laguna, J; Pezzoli, G; Pozzi, NG | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
| Klein, S; Wollmer, E | 1 |
| Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z | 1 |
| Etminan, N; Rahmanifar, E; Yoosefian, M | 1 |
| Chang, MC; Lee, HD | 1 |
| Bloem, BR; Dirkx, MF; Hallett, M; Helmich, RC; Zach, H | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Lim, SY; Ng, RX; Tan, AH | 1 |
| Hoppe, M; Koziolek, M; Schneider, F; Weitschies, W | 1 |
| Arnulfo, G; Canessa, A; Isaias, IU; Marotta, G; Olivieri, C; Palmisano, C; Pezzoli, G; Pozzi, NG; Turco, F; Volkmann, J | 1 |
| Ali, M; Chandel, TI; Jahan, I; Khan, RH; Masroor, A; Nayeem, SM; Siddique, IA; Uversky, VN; Zaidi, N; Zaman, M | 1 |
| Denibaud, AS; Drieu La Rochelle, C; Loiodice, S; Méot, B; Montagne, P; Rion, B; Viel, R; Wing Young, H | 1 |
| Begemann, M; Damen, R; Elbracht, M; Häusler, M; Knopp, C; Kurth, I; Mull, M; Müller, B; Stoppe, A | 1 |
| Chen, L; Deng, F; Liu, X | 1 |
| Chen, Y; Lian, Y; Wang, C; Wang, R; Zhang, Y | 1 |
| Brandt, G; Canessa, A; Frigo, CA; Isaias, IU; Leporini, A; Maltese, V; Palmisano, C; Pezzoli, G; Pozzi, NG; Volkmann, J | 1 |
| Iggena, D; Klein, C; Rasińska, J; Sparenberg, M; Steiner, B; Winter, Y | 1 |
| Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L | 1 |
| Ding, YP; Lai, WL; Liu, HF; Qu, Y; Wang, L; Xin, YR; Xu, Y; Zhu, FQ; Zhu, Y | 1 |
| Carriere, J; Fukami, T; Hisada, H; Hoshino, T; Koide, T; Okayama, A; Yamamoto, Y | 1 |
| Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B | 1 |
| Dong, HY; Feng, JY; Jia, FY; Shan, L; Yue, XJ | 1 |
| Cools, R; den Ouden, HEM; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, AJ; Zach, H | 1 |
| Biacchi, D; Cariddi, LP; Espay, AJ; Franciotta, D; Gastaldi, M; Mauri, M; Sturchio, A; Versino, M | 1 |
| Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Qiao, JY; Wang, Y; Zang, QM | 1 |
| Castro, JC; Dalle, CR; Domingues-Hajj, PMS; Grandi-Miranda, FT; Milhomem, CBSS; Morais, BA; Reis, DM; Santos, UM; Silva, DJ; Souza, JT; Vilela-Filho, O | 1 |
| Che, NN; Chen, SY; Li, X; Ma, JJ; Yang, HQ | 1 |
| Babel, N; Bertram, S; Büchner, N; Doevelaar, A; Mühlberger, D; Racovitan, D; Rohn, B; Seibert, FS; Seidel, M; Toma, D; Wang, S; Westhoff, TH | 1 |
| Al-Kaleel, A; Aygün, H; Erbaş, O | 1 |
| Baba, Y; Futamura, A; Kinno, R; Nabeshima, Y; Nomoto, S; Osakabe, Y; Shoji, D; Takahashi, S; Yasumoto, T | 1 |
| Carlier, PR; Dye, KJ; O'Hara, M; Santos, W; Sobrado, P; Vogelaar, NJ; Yang, Z | 1 |
| Araujo, MDS; da Silva, EP; Kunita, MH; Matos, R; Medeiros, RA | 1 |
| Chan, P; Chhetri, JK; Su, D; Su, Y; Xu, B | 1 |
| Cai, ZJ; Chang, PP; Li, YZ; Wei, LK; Yang, L; Zhang, GY; Zhang, XL; Zhang, YP; Zhu, DN | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Gao, F; Gao, L; Miao, J; Yang, Y | 1 |
23 review(s) available for levodopa and benserazide
| Article | Year |
|---|---|
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Levodopa.
Topics: Benserazide; Drug Interactions; Hepatic Encephalopathy; Humans; Huntington Disease; Levodopa; Melanoma; Parkinson Disease; Pituitary Function Tests | 1975 |
Two types of dopamine receptors in behavioral regulation.
Topics: Animals; Behavior; Behavior, Animal; Benserazide; Brain; Carbidopa; Cats; Dopamine; Haloperidol; Humans; Levodopa; Psychomotor Agitation; Rats; Receptors, Dopamine; Reserpine; Snails; Tranquilizing Agents | 1978 |
Decarboxylase inhibitors.
Topics: Amino Acids; Animals; Behavior; Behavior, Animal; Benserazide; Brain; Capillaries; Carboxy-Lyases; Catecholamines; Chemical Phenomena; Chemistry; Dihydroxyphenylalanine; Humans; Levodopa; Mice; Rabbits; Rats; Time Factors | 1975 |
Compulsive gnawing.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Benserazide; Dextroamphetamine; Dihydroxyphenylalanine; Dopamine; Iproniazid; Levodopa; Male; Methyldopa; Methyltyrosines; Rats; Serotonin; Structure-Activity Relationship; Time Factors | 1976 |
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Topics: Benserazide; Binding Sites; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Hydrazines; Kinetics; Levodopa; Liver Function Tests; Parkinson Disease | 1976 |
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism | 1987 |
The hydrodynamically balanced system: a novel principle of controlled drug release.
Topics: Administration, Oral; Benserazide; Biological Availability; Capsules; Delayed-Action Preparations; Drug Combinations; Humans; Hydrazines; Levodopa | 1987 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Growth hormone secretion in neurological disorders.
Topics: Benserazide; Disease Models, Animal; Dopamine; Growth Hormone; Humans; Huntington Disease; Levodopa; Nervous System Diseases; Parkinson Disease | 1981 |
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Receptors, Dopamine | 1980 |
[Vascular hemi-parkinson disease].
Topics: Aged; Aspirin; Benserazide; Brain Ischemia; Drug Therapy, Combination; Female; Functional Laterality; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Neostriatum; Parkinson Disease | 1993 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Syndrome; Tomography, X-Ray Computed | 1993 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
[Parkinson's disease and pregnancy: case report and literature review].
Topics: Adult; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2000 |
[Idiopathic Parkinson's disease: practical hints for the treatment].
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Benserazide; Cholinesterase Inhibitors; Clozapine; Dementia; Depression; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep Wake Disorders; Time Factors | 2005 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation | 2014 |
Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Topics: Acupuncture Therapy; Benserazide; Combined Modality Therapy; Dopamine Agents; Drug Combinations; Humans; Levodopa; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Dopa-responsive dystonia caused by tyrosine hydroxylase deficiency: Three cases report and literature review.
Topics: Benserazide; Child; Child, Preschool; Dopamine Agents; Dystonic Disorders; Humans; Levodopa; Male; Tyrosine 3-Monooxygenase | 2020 |
Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
136 trial(s) available for levodopa and benserazide
| Article | Year |
|---|---|
The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.
Topics: Adult; Affect; Antipsychotic Agents; Anxiety; Basal Ganglia Diseases; Benserazide; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Drug Combinations; Emotions; Humans; Hydrazines; Levodopa; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Social Behavior | 1975 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Vomiting | 1975 |
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Injections, Intravenous; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Time Factors | 1977 |
Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Topics: Aged; Benserazide; Carbidopa; Consumer Behavior; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Studies on pituitary hormones and releasing hormones in depression and sexual impotence.
Topics: 5-Hydroxytryptophan; Benserazide; Bipolar Disorder; Clinical Trials as Topic; Depression; Erectile Dysfunction; Female; Fenclonine; Humans; Imipramine; Insulin; Levodopa; Male; Pituitary Hormone-Releasing Hormones; Pituitary Hormones | 1975 |
[Levodopa and decarboxylase inhibitors in Parkinson's disease].
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1977 |
Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.
Topics: Administration, Oral; Adolescent; Adult; Benserazide; Bromocriptine; Clinical Trials as Topic; Drug Interactions; Ergolines; Female; Humans; Hydrazines; Levodopa; Male; Metergoline; Methysergide; Middle Aged; Pituitary Gland; Pituitary Gland, Anterior; Prolactin; Secretory Rate; Stimulation, Chemical; Time Factors | 1977 |
Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1978 |
Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
Topics: Activities of Daily Living; Aged; Benserazide; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
[Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
Topics: Adult; Benserazide; Brain; Carbidopa; Clinical Trials as Topic; Confusion; Electrocardiography; Electroencephalography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Stomach Diseases; Tomography, X-Ray Computed | 1979 |
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Levodopa with benserazide or carbidopa in Parkinson disease.
Topics: Benserazide; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Ergolines; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
[Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Topics: Benserazide; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1976 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Serine | 1975 |
Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Piperazines; Piribedil; Reflex, Monosynaptic; Tremor | 1975 |
Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
Topics: Benserazide; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease; Prospective Studies; Psychomotor Performance | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Sleep Initiation and Maintenance Disorders; Sleep Stages; Temazepam | 1991 |
A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Topics: Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine; Drug Combinations; Female; Follow-Up Studies; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Motor Skills; Multicenter Studies as Topic; Neurologic Examination; Parkinson Disease | 1990 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Madopar HBS in nocturnal symptoms of Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Sleep Stages | 1990 |
Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
Topics: Adult; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Effect of levodopa on contrast sensitivity and scotomas in human amblyopia.
Topics: Adult; Amblyopia; Analysis of Variance; Benserazide; Contrast Sensitivity; Drug Combinations; Humans; Levodopa; Reference Values; Scotoma; Visual Acuity | 1990 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Is there a common dopaminergic basis of time perception and reaction time?
Topics: Adult; Benserazide; Brain; Clinical Trials as Topic; Dopamine Agents; Double-Blind Method; Drug Combinations; Haloperidol; Humans; Hydrazines; Levodopa; Male; Reaction Time; Receptors, Dopamine; Time Perception | 1989 |
A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
Topics: Activities of Daily Living; Aged; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
Levodopa in restless legs.
Topics: Adolescent; Adult; Aged; Benserazide; Capsules; Child; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Lactose; Levodopa; Male; Middle Aged; Restless Legs Syndrome | 1986 |
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Ergolines; Humans; Hydrazines; Infusion Pumps; Levodopa; Lisuride; Parkinson Disease; Severity of Illness Index | 1988 |
A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Movement; Parkinson Disease | 1988 |
Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Topics: Benserazide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Periodicity; Reaction Time; Restless Legs Syndrome; Sleep; Surveys and Questionnaires | 1988 |
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Capsules; Consumer Behavior; Deglutition Disorders; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Random Allocation; Tablets | 1988 |
Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 1987 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Biological Availability; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Infant, Newborn; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Secondary; Tremor | 1987 |
[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1987 |
Mesulergine in early Parkinson's disease: a double blind controlled trial.
Topics: Aged; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1986 |
Restless legs syndrome treatment with dopaminergic drugs.
Topics: Adult; Aged; Benserazide; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Piribedil; Random Allocation; Restless Legs Syndrome; Sleep Initiation and Maintenance Disorders | 1987 |
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Topics: Activities of Daily Living; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Evaluation Studies as Topic; Gastrointestinal Diseases; Gymnastics; Humans; Hydrazines; Levodopa; Parkinson Disease; Speech Therapy | 1973 |
Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 1974 |
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Lipidoses; Psychoses, Substance-Induced; Syndrome | 1982 |
[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Topics: Aged; Benserazide; Bromocriptine; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Random Allocation; Time Factors | 1984 |
Administration of levodopa for relief of herpes zoster pain.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Herpes Zoster; Humans; Levodopa; Male; Middle Aged; Pain; Random Allocation | 1981 |
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Topics: Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1991 |
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Memory, Short-Term; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Parkinson Disease; Psychomotor Performance | 1995 |
[Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1994 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure | 1995 |
L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Polysomnography; Quality of Life; Restless Legs Syndrome; Sleep Wake Disorders; Uremia | 1995 |
'Atypical' tremor.
Topics: Benserazide; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Combinations; Electromyography; Female; Humans; Infant; Levodopa; Male; Parkinson Disease; Propranolol; Tremor | 1995 |
A study on the effect and tolerance of lisuride on Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Disease Progression; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Psychiatric Status Rating Scales | 1996 |
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Tolcapone | 1995 |
Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Denmark; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease | 1996 |
Dopaminergic modulation of semantic network activation.
Topics: Adult; Benserazide; Cerebral Cortex; Dopamine; Double-Blind Method; Female; Humans; Levodopa; Male; Mental Recall; Nerve Net; Paired-Associate Learning; Receptors, Dopamine; Semantics | 1996 |
The effect of catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial.
Topics: Adult; Benserazide; Bruxism; Cross-Over Studies; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Electromyography; Female; Humans; Levodopa; Male; Polysomnography; Sleep Wake Disorders | 1997 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method | 1996 |
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Patient Dropouts; Psychomotor Agitation | 1997 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[The application of the pattern visual-evoked potential in the diagnosis and treatment of amblyopia].
Topics: Adolescent; Adult; Amblyopia; Benserazide; Child; Child, Preschool; Dopamine Agents; Drug Combinations; Evoked Potentials, Visual; Female; Humans; Levodopa; Male | 1995 |
Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Benserazide; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Levodopa; Male; Middle Aged; Tyrosine | 1997 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline | 1997 |
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Topics: Adjuvants, Pharmaceutic; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Biological Availability; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Male; Nitrophenols; Reference Values; Tolcapone | 1997 |
Postural tremor of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Propranolol; Tremor | 1994 |
Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy.
Topics: Adult; Aged; Benserazide; Diabetic Neuropathies; Dopamine Agents; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Palliative Care; Peripheral Nervous System Diseases | 1998 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
Topics: Benserazide; Biological Availability; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Humans; Levodopa; Metabolic Clearance Rate; Time Factors; Tyrosine | 1998 |
The effects of incentive on antisaccades: is a dopaminergic mechanism involved?
Topics: Adult; Benserazide; Cognition; Dopamine; Dopamine Agents; Economics; Fixation, Ocular; Frontal Lobe; Humans; Levodopa; Male; Memory; Motivation; Personality; Psychomotor Performance; Reflex; Saccades; Self-Evaluation Programs | 1997 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Tyrosine | 1999 |
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone | 1999 |
Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions.
Topics: Adult; Benserazide; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Male; Movement Disorders; Nocturnal Paroxysmal Dystonia; Paraplegia; Polysomnography; Restless Legs Syndrome | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
[Efficiency of new forms of madopar in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2000 |
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease.
Topics: Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 2001 |
Delay of simple reaction time after levodopa intake.
Topics: Adult; Aged; Antiparkinson Agents; Behavior; Benserazide; Cognition; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychiatric Status Rating Scales; Reaction Time; Reference Values | 2001 |
Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Benserazide; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension; Hypotension, Orthostatic; Levodopa; Male; Parkinsonian Disorders; Postprandial Period; Posture; Reference Values | 2001 |
Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects.
Topics: Adult; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Cross-Over Studies; Dopamine; Dopamine Agents; Double-Blind Method; Electromyography; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Mental Processes; Psychomotor Performance; Reaction Time | 2002 |
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Methyldopa; Reference Values | 2003 |
Effects of food on the pharmacokinetics of levodopa in a dual-release formulation.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Female; Food; Food-Drug Interactions; Half-Life; Humans; Levodopa; Male; Time Factors; Tyrosine | 2003 |
Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Sleep; Treatment Outcome | 2003 |
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine | 2003 |
One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Prospective Studies; Quality of Life; Restless Legs Syndrome; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2003 |
Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Benserazide; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Polysomnography; Restless Legs Syndrome; Surveys and Questionnaires; Time Factors; Treatment Outcome; Valproic Acid | 2004 |
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Biological Availability; Dihydroxyphenylalanine; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Tyrosine | 2004 |
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase; Drug Interactions; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pharmacogenetics; Polymorphism, Genetic; Reaction Time | 2005 |
[Madopar in the complex therapy of ischemic insult].
Topics: Aged; Aged, 80 and over; Benserazide; Blood Pressure; Brain Ischemia; Cognition; Dopamine Agents; Drug Administration Schedule; Drug Combinations; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Stroke; Treatment Outcome | 2005 |
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Down-Regulation; Enzyme Inhibitors; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Raphe Nuclei; Serotonin; Tyrosine | 2007 |
The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Topics: Adult; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Asian People; Benserazide; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Indoles; Levodopa; Linear Models; Male; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2007 |
Dopaminergic influences on changes in human tactile acuity induced by tactile coactivation.
Topics: Adult; Analysis of Variance; Benserazide; Discrimination Learning; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Sensory Thresholds; Time Factors; Touch | 2007 |
[Clinical observation on abdominal acupuncture plus Madopa for treatment of Parkinson's disease].
Topics: Abdomen; Acupuncture Therapy; Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Medicine, Chinese Traditional; Middle Aged; Parkinson Disease; Phytotherapy; Prospective Studies; Syndrome; Treatment Outcome | 2007 |
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Topics: Adult; Aged; Antiemetics; Antiparkinson Agents; Benserazide; Domperidone; Drug Administration Schedule; Exercise Test; Exercise Therapy; Exercise Tolerance; Hand Strength; Humans; Hydrocortisone; Levodopa; Middle Aged; Muscle Strength; Parkinson Disease; Physical Endurance; Physical Fitness; Stress, Physiological; Treatment Outcome | 2008 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Topics: Acupuncture Therapy; Aged; Benserazide; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2008 |
L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study.
Topics: Adult; Benserazide; Brain Mapping; Cognition; Corpus Striatum; Dopamine Agents; Double-Blind Method; Drug Combinations; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Movement; Neural Pathways; Neuropsychological Tests; Oxygen; Probability | 2009 |
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Topics: Administration, Oral; Adult; Area Under Curve; Azepines; Benserazide; China; Chromatography, Liquid; Cross-Over Studies; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Tablets; Tandem Mass Spectrometry | 2009 |
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine; Young Adult | 2009 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Area Under Curve; Argentina; Benserazide; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Tablets; Therapeutic Equivalency; Young Adult | 2011 |
Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Topics: Adult; Aged; Benserazide; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Sleep; Treatment Outcome | 2011 |
Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans.
Topics: Administration, Oral; Adult; Benserazide; Dopamine Agents; Double-Blind Method; Drug Combinations; Evoked Potentials, Auditory; Female; Humans; Levodopa; Loudness Perception; Male; Young Adult | 2012 |
[Effects of bushenhuoxue granules on sleep quality in Parkinson's patients].
Topics: Aged; Aged, 80 and over; Benserazide; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2011 |
[Effects of "attenuation and synergia" for Bushenhuoxue Granules on Parkinson's patients].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Constipation; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Treatment Outcome; Urination Disorders | 2012 |
Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Topics: Benserazide; Data Interpretation, Statistical; Drug Combinations; Drugs, Chinese Herbal; Humans; Levodopa; Medicine, Chinese Traditional; Parkinson Disease; Phytotherapy; Piribedil; Quality of Life | 2013 |
Dissociating distractor-filtering at encoding and during maintenance.
Topics: Adult; Ascorbic Acid; Attention; Benserazide; Cell Phone; Control Groups; Double-Blind Method; Female; Humans; Levodopa; Male; Memory, Short-Term; Orientation; Pattern Recognition, Visual; Perceptual Masking; Placebo Effect; Reaction Time; Sensory Gating; Young Adult | 2014 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2015 |
Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.
Topics: Adult; Aged; Appetite; Benserazide; Breath Tests; Caprylates; Dopamine Agents; Drug Combinations; Gastric Emptying; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2015 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Periodicity; Piribedil; Postural Balance; Pramipexole; Walking | 2015 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Neural correlates underlying micrographia in Parkinson's disease.
Topics: Aged; Attention; Basal Ganglia; Benserazide; Brain Mapping; Case-Control Studies; Cerebellum; Drug Combinations; Female; Gyrus Cinguli; Handwriting; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles | 2017 |
Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Motor Activity; Mucuna; Parkinson Disease; Phytotherapy; Powders; Seeds; Treatment Outcome | 2017 |
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Topics: Adult; Aged; Benserazide; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Combinations; Drugs, Generic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2019 |
Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson's disease: Results from a single-center trial.
Topics: Benserazide; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Risk Factors | 2023 |
524 other study(ies) available for levodopa and benserazide
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Parkinson Disease; Pyridones; Recombinant Proteins; Structure-Activity Relationship | 2012 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
Topics: 5-Hydroxytryptophan; Amino Acids; Animals; Benserazide; Brain; Cyclopropanes; Glucose; Hepatectomy; Hydrazines; Levodopa; Male; Monoamine Oxidase Inhibitors; Phenyl Ethers; Pyridoxal Phosphate; Rats | 1979 |
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Benserazide; Callitrichinae; Disease Models, Animal; Drug Therapy, Combination; Haloperidol; Haplorhini; Hydroxydopamines; Hypothalamus; Levodopa; Locus Coeruleus; Male; Torticollis | 1979 |
A comparative study on the uptake and subsequent decarboxylation of monoamine precursors in cerebral microvessels.
Topics: 5-Hydroxytryptophan; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Blood-Brain Barrier; Brain; Cats; Cattle; Cricetinae; Decarboxylation; Dogs; Droxidopa; Female; Guinea Pigs; Haplorhini; Humans; Levodopa; Male; Mice; Microcirculation; Microscopy, Fluorescence; Rabbits; Rats; Serine; Species Specificity; Swine | 1979 |
Long-term L-dopa pretreatment of mice: central receptor subsensitivity or supersensitivity?
Topics: Animals; Apomorphine; Benserazide; Dextroamphetamine; Drug Interactions; Levodopa; Male; Mice; Mice, Inbred Strains; Motor Activity; Receptors, Adrenergic; Time Factors | 1979 |
[Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats].
Topics: Animals; Benserazide; Blood Pressure; Carbon Dioxide; Cerebrovascular Circulation; Female; Heart Rate; Hemodynamics; Hydrazines; Hypoxia; Levodopa; Motor Activity; Oxygen; Rats | 1975 |
Effects of levodopa and dopamine of plasma glucose concentration in mice.
Topics: Animals; Apomorphine; Benserazide; Blood Glucose; Carbidopa; Cyproheptadine; Dopamine; Fatty Acids, Nonesterified; Fenclonine; Haloperidol; Insulin; Levodopa; Liver Glycogen; Male; Methysergide; Mice; Nialamide; Pargyline; Pimozide; Time Factors | 1977 |
Dopaminergic control of adenohypophyseal growth after oestrogens: negative results with L-DOPA, RO-4-4602, alpha-methyl-DOPA, apomorphine, haloperidol, pyridoxine and cyproheptadine.
Topics: Animals; Apomorphine; Benserazide; Cyproheptadine; Estrogens; Haloperidol; Levodopa; Pituitary Gland, Anterior; Pyridoxine; Rats; Thyroxine-Binding Proteins | 1978 |
Automatic registration of behaviour related to dopamine and noradrenaline transmission.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Dopamine; Dose-Response Relationship, Drug; Isotonic Solutions; Levodopa; Male; Methods; Motor Activity; Norepinephrine; Phenoxybenzamine; Rats; Synaptic Transmission | 1976 |
Effects of dopaminergic stimulants on cyclic nucleotide levels in mouse brain in vivo.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Benserazide; Brain; Cerebellum; Cyclic AMP; Cyclic GMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoquinolines; Levodopa; Male; Mice; Nucleotides, Cyclic; Stereotyped Behavior | 1976 |
Proposal of a new model with dopaminergic-cholinergic interactions for neuropharmacological investigations.
Topics: Acetylcholine; Animals; Apomorphine; Atropine; Benserazide; Bromocriptine; Central Nervous System; Dextroamphetamine; Dopamine; Extrapyramidal Tracts; Haloperidol; Levodopa; Models, Neurological; Motor Activity; Physostigmine; Piribedil; Planarians; Reserpine; Synaptic Transmission; Turbellaria | 1975 |
The role of dopamine and serotonin in the prolongation of post-decapitation convulsions in mice.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Decerebrate State; Ditiocarb; Dopamine; Fenclonine; Haloperidol; Levodopa; Male; Mice; Norepinephrine; Seizures; Serotonin; Serotonin Antagonists; Time Factors | 1976 |
Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices.
Topics: Amphetamine; Animals; Benserazide; Brocresine; Bucladesine; Calcium; Carboxy-Lyases; Catecholamines; Corpus Striatum; Dopamine; Drug Interactions; In Vitro Techniques; Levodopa; Male; Phosphodiesterase Inhibitors; Potassium; Rats; Reserpine; Stimulation, Chemical; Xanthines | 1977 |
Experimental aggression and bruxism in rats.
Topics: Aggression; Animals; Apomorphine; Benserazide; Bruxism; Ditiocarb; Electroshock; Humans; Iproniazid; Levodopa; Male; Rats; Stereotyped Behavior | 1979 |
Adenosine 3':5'-monophosphate-dependent in vitro phosphorylation of synaptosomal membrane proteins from rat corpus striatum following systemic administration of L-DOPA and bromocriptine.
Topics: Animals; Benserazide; Bromocriptine; Corpus Striatum; Cyclic AMP; In Vitro Techniques; Levodopa; Membrane Proteins; Phosphorylation; Rats; Stimulation, Chemical; Synaptic Membranes | 1979 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; Carbon Radioisotopes; Depression, Chemical; Dopamine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H1 Antagonists; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Time Factors; Trihexyphenidyl | 1975 |
Interaction of N-(DL-seryl)N'-(2,3,4-trihydroxybenzyl)-hydrazine with L-dopa decarboxylase from pig kidney.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Dopa Decarboxylase; Hydrazines; Kidney; Kinetics; Levodopa; Protein Binding; Spectrophotometry; Spectrophotometry, Ultraviolet; Swine; Tyrosine | 1977 |
Effects of L-dopa and L-5-hydroxytryptophan on locomotor activity of the rat after selective or combined destruction of central catecholamine and serotonin neurons.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Body Weight; Catecholamines; Humans; Levodopa; Locomotion; Male; Neurons; Psychomotor Agitation; Rats; Serotonin; Stereotyped Behavior; Telencephalon | 1979 |
Evidence for a central monoaminergic influence on urinary bladder control mechanism.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Carbidopa; Catecholamines; Dopamine; Levodopa; Male; Norepinephrine; Parasympathetic Nervous System; Pressure; Rats; Spiperone; Urinary Bladder; Urodynamics | 1979 |
Apomorphine revived: fortified, prolonged, and improved therapeutical effect.
Topics: Aged; Alcoholism; Apomorphine; Benserazide; Capsules; Drug Combinations; History, 18th Century; History, 20th Century; Humans; Levodopa; Male; Substance-Related Disorders; Tablets | 1978 |
Dose-related levodopa-induced haemolytic anaemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Benserazide; Dose-Response Relationship, Drug; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 1977 |
Pharmaceutical review: salbutamol - madopar - isocal.
Topics: Albuterol; Australia; Benserazide; Humans; Hydrazines; Levodopa; Lung Diseases; Parenteral Nutrition; Parkinson Disease | 1978 |
Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Female; In Vitro Techniques; Kinetics; Levodopa; Liver; Male; Rats; Transaminases | 1979 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
Topics: Adolescent; Adult; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Hydrazines; Levodopa; Male; Micrococcus; Middle Aged; Nicotinamidase; Nicotinic Acids; Parkinson Disease; Tryptophan | 1979 |
[Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
Topics: Adolescent; Adult; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Synergism; Fatty Acids, Nonesterified; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Pituitary Gland; Secretory Rate | 1979 |
Lupus-like autoimmune syndrome after levodopa and benserazide.
Topics: Autoimmune Diseases; Benserazide; Humans; Hydrazines; Levodopa; Lupus Erythematosus, Systemic; Male; Middle Aged; Syndrome | 1979 |
Role of dopaminergic and noradrenergic mechanisms in Metrazole convulsions in mice.
Topics: Animals; Apomorphine; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Clonidine; Dopamine; Drug Interactions; Female; Haloperidol; Levodopa; Male; Methyltyrosines; Mice; Norepinephrine; Pentylenetetrazole; Phenoxybenzamine; Propranolol; Receptors, Dopamine; Reserpine; Seizures; Tetrabenazine | 1979 |
["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Coombs Test; Female; Humans; Hydrazines; Levodopa; Parkinson Disease | 1979 |
[On a muscular dystony case from manganism. Therapeutic clinic considerations (author's transl)].
Topics: Benserazide; Diazepam; Dystonia; Haloperidol; Humans; Hydrazines; Levodopa; Male; Manganese; Middle Aged | 1979 |
L-Dopa inhibits prolactin secretion in proestrous rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Female; Levodopa; Pregnancy; Proestrus; Prolactin; Rats; Time Factors | 1977 |
Where is L-DOPA decarboxylated in the striatum after 6-hydroxydopamine nigrotomy?
Topics: Animals; Benserazide; Blood-Brain Barrier; Capillaries; Corpus Striatum; Decarboxylation; Dopamine; Endothelium; Female; Humans; Hydroxydopamines; Levodopa; Methyldopa; Premedication; Rats; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1978 |
[Relationship between gnawing compulsion and central dopaminergic mechanism in guinea pigs (author's transl)].
Topics: Amphetamine; Animals; Apomorphine; Behavior; Benserazide; Dopamine; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Methyltyrosines; Pimozide; Stereotyped Behavior | 1979 |
Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Treating parkinsonism with L-dopa and carboxylase inhibitor.
Topics: Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
Topics: Benserazide; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Posture | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
The effect of L-dopa on peripheral sympathetic nerve function: role of presynaptic dopamine receptors.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Blood Pressure; Dogs; Dopamine; Dopamine beta-Hydroxylase; Drug Interactions; Female; Heart Rate; Levodopa; Male; Pimozide; Receptors, Dopamine; Sympathetic Nervous System | 1978 |
L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment.
Topics: Animals; Benserazide; Cell Line; Drug Synergism; Leucine; Levodopa; Male; Mice; Neoplasms, Experimental; Neuroblastoma; Thymidine; Uridine | 1978 |
Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
Topics: Adrenal Medulla; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Catecholamines; Levodopa; Melanins; Melanoma; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Rats | 1978 |
Apomorphine and L-DOPA lower ejaculation threshold in the male rat.
Topics: Animals; Apomorphine; Benserazide; Brain; Carboxy-Lyases; Ejaculation; Levodopa; Male; Pimozide; Rats; Receptors, Dopamine; Serotonin; Sexual Behavior, Animal | 1978 |
[Effects of benserazide administration on prolactin secretion].
Topics: Acromegaly; Adult; Benserazide; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Pituitary Gland, Anterior; Prolactin | 1978 |
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Topics: Benserazide; Brain; Bromocriptine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Furosemide; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Parkinson Disease; Posture; Renin | 1978 |
[Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopa Decarboxylase; Hydrazines; Levodopa; Male; Pyridoxine; Rats | 1978 |
Long term treatment with L-deprenyl.
Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
On certain effects of dopaminergic agents in pentylenetetrazol convulsions.
Topics: Amantadine; Animals; Benserazide; Dextroamphetamine; Dopamine; Drug Interactions; Haloperidol; Levodopa; Male; Mice; Pentylenetetrazole; Rats; Seizures | 1978 |
Effects of catecholic tetrahydroisoquinolines on endogenous catecholamines.
Topics: Animals; Benserazide; Brain; Catecholamines; Catechols; Dopamine; Isoquinolines; Levodopa; Male; Norepinephrine; Rats; Salsoline Alkaloids; Tetrahydropapaveroline | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
[The effect of exogenous catecholamines on the cardiac rhythm and thermoregulation of hibernating hedgehogs (Erinaceus europaeus L.)].
Topics: Animals; Benserazide; Body Temperature Regulation; Carboxy-Lyases; Catecholamines; Electrodes, Implanted; Heart Rate; Hibernation; Levodopa; Norepinephrine | 1975 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
Topics: Adult; Benserazide; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1976 |
Serum dopamine-beta-hydroxylase in parkinsonism.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine beta-Hydroxylase; Humans; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease | 1977 |
[Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease, Secondary | 1977 |
Effect of L-dopa on polycythemia.
Topics: Aged; Benserazide; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Polycythemia Vera | 1977 |
Levodopa in parkinsonism.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Time Factors | 1977 |
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Topics: Benserazide; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Time Factors | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Interelationships between dopaminergic and cholinergic systems in the cerebral cortex.
Topics: Acetylcholine; Animals; Apomorphine; Benserazide; Bromocriptine; Cats; Cerebral Cortex; Dopamine; Female; Haloperidol; Levodopa; Male; Parasympathetic Nervous System; Rats; Time Factors | 1977 |
Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
Topics: Alcohol Oxidoreductases; Aldehyde Oxidoreductases; Animals; Benserazide; Drug Interactions; Hydrazines; Levodopa; Liver; Male; Rats; Time Factors | 1977 |
Effect of L-DOPA analogues in Sidman avoidance performance in mice.
Topics: Animals; Avoidance Learning; Benserazide; Brain; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Methyldopa; Mice; Motor Activity; Norepinephrine; Serotonin | 1977 |
Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
Topics: Alcohol Drinking; Amino Acids; Animals; Benserazide; Carbidopa; Carboxy-Lyases; Choice Behavior; Drug Interactions; Levodopa; Male; Rats; Time Factors | 1977 |
["Beginning and end of dose" dyskinesias caused by L-DOPA].
Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Central action of beta-phenylethylamine derivatives (10). Effect of L-Dopa on metaraminol induced motor activity (author's transl)].
Topics: Animals; Benserazide; Brain; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Metaraminol; Mice; Motor Activity; Norepinephrine; Serotonin; Time Factors | 1977 |
Is the release of noradrenaline necessary for self-stimulation of the brain?
Topics: Amphetamine; Animals; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Clonidine; Disulfiram; Levodopa; Male; Naphazoline; Nerve Endings; Norepinephrine; Oxymetazoline; Phenylephrine; Rats; Receptors, Drug; Reserpine; Self Stimulation | 1976 |
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Patient Dropouts; Time Factors | 1976 |
Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Switzerland | 1976 |
Cardiovascular responses to acute hypoxia in dogs pretreated with benserazide and L-DOPA.
Topics: Animals; Benserazide; Blood Gas Analysis; Blood Pressure; Cardiac Output; Dogs; Heart Rate; Hemodynamics; Hydrazines; Hypoxia; Levodopa; Regional Blood Flow; Respiration; Vascular Resistance | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Interactions; Humans; Hydrazines; Levodopa; Parkinson Disease; Pyridoxine; Rats | 1976 |
Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
Topics: Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1976 |
A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Benserazide; Brain; Brocresine; Carbidopa; Dopamine; Hydrazines; Levodopa; Male; Methyldopa; Rats; Time Factors | 1976 |
Prolonged symptoms of brain dysfunction--adverse effect of levodopa.
Topics: Aged; Benserazide; Brain Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Time Factors | 1976 |
[Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
Topics: Adolescent; Benserazide; Child; Disulfiram; Drug Synergism; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Propranolol | 1976 |
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Topics: Adult; Aged; Benserazide; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Reinstatement of vaginal cycles in aged female rats.
Topics: Aging; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Estrus; Female; Fusaric Acid; Hypophysectomy; Levodopa; Phenoxybenzamine; Pimozide; Pregnancy; Propranolol; Rats; Tyrosine; Vagina | 1976 |
Effects of catecholaminergic drugs on systems of reward and punishment in experiments on cats.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Benserazide; Catecholamines; Cats; Disulfiram; Electric Stimulation; Electrodes, Implanted; Levodopa; Male; Punishment; Reward | 1976 |
The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
Topics: Amino Acids; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Glucose; Brain; Brain Chemistry; Drug Interactions; Glucose; Hydrazines; Levodopa; Rats | 1976 |
[Endogenous catecholamines and excitability of the superior cervical ganglion of the rat (author's transl)].
Topics: Animals; Benserazide; Catecholamines; Chromaffin System; Ganglia, Autonomic; Guanethidine; Iproniazid; Levodopa; Male; Rats; Rats, Inbred Strains; Reserpine; Tyrosine | 1976 |
[5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
Topics: Adult; Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat.
Topics: Animals; Apomorphine; Benserazide; Clonidine; Dextroamphetamine; Dopamine; Female; Haloperidol; Hypophysectomy; Levodopa; Male; Methyltyrosines; Piribedil; Pituitary Gland; Prolactin; Rats; Reserpine; Sulpiride; Transplantation, Homologous | 1976 |
A histochemical study on the central effect of monoamine precursors.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Brain Chemistry; Capillaries; Cerebral Ventricles; Dopamine; Drug Combinations; Hydrazines; Levodopa; Male; Median Eminence; Norepinephrine; Rats; Serotonin; Substantia Nigra | 1975 |
Central D-fenfluramine action.
Topics: Animals; Anura; Benserazide; Body Temperature; Brain; Depression, Chemical; Fenfluramine; Hydroxyindoleacetic Acid; Levodopa; Male; Mice; Motor Activity; Rana temporaria; Rats; Reflex; Serotonin | 1975 |
Histochemical characterization of the monoamine-containing cells of the adenohypophysis in the Chinese quail.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Dopamine; Levodopa; Microscopy, Fluorescence; Nialamide; Pituitary Gland; Pituitary Gland, Anterior; Quail; Serotonin | 1976 |
The effect of amitriptyline, desipramine and imipramine on the vivo brain synthesis of 3H-noradrenaline from 3H-L-dopa in the rat.
Topics: 3-Methoxy-4-hydroxyphenylethanol; 3,4-Dihydroxyphenylacetic Acid; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Benserazide; Brain; Chromatography, Thin Layer; Desipramine; Dopamine; Imipramine; Levodopa; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Normetanephrine; Rats; Tryptamines | 1975 |
Effects of anti-parkinsonian drugs on the motor activity and EEG of cats with subthalamic lesions.
Topics: Amantadine; Animals; Antiparkinson Agents; Attention; Behavior, Animal; Benserazide; Cats; Cerebral Cortex; Cortical Synchronization; Dextroamphetamine; Diencephalon; Electroencephalography; Functional Laterality; Levodopa; Motor Activity; Neural Pathways; Reticular Formation | 1975 |
Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
Topics: Aged; Benserazide; Blood Pressure; Cerebrovascular Circulation; Dopa Decarboxylase; Drug Combinations; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male | 1975 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic | 1975 |
Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1975 |
Behavioral effects in rats following intrastriatal microinjection of manganese.
Topics: Aggression; Animals; Behavior, Animal; Benserazide; Calcium Chloride; Caudate Nucleus; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxydopamines; Levodopa; Male; Manganese; Methyltyrosines; Motor Activity; Pargyline; Rats; Time Factors | 1975 |
Does chronic morphine treatment induce a supersensitivity of dopamine receptors in rat brain?
Topics: Animals; Apomorphine; Benserazide; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Levodopa; Male; Morphine; Probenecid; Rats; Receptors, Drug; Stereotyped Behavior; Substance Withdrawal Syndrome | 1975 |
Ethanol narcosis in mice: effects of L-dopa, its metabolites and other experimental variables.
Topics: Age Factors; Animals; Benserazide; Brain; Ethanol; Levodopa; Male; Mice; Sleep; Temperature | 1975 |
Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats.
Topics: Animals; Benserazide; Brain Chemistry; Carbon Dioxide; Cerebrovascular Circulation; Dopamine; Female; Hydrazines; Hypoxia; Levodopa; Motor Activity; Norepinephrine; Oxygen; Rats | 1975 |
The action of L-dopa in rats with the raphe nuclei lesions.
Topics: Animals; Benserazide; Body Temperature; Brain; Carbidopa; Electric Stimulation; Hydroxyindoleacetic Acid; Levodopa; Rats; Serotonin; Thalamic Nuclei; Time Factors | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Metanephrine; Middle Aged; Normetanephrine; Parkinson Disease; Tyramine; Vanilmandelic Acid | 1975 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa].
Topics: Benserazide; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Time Factors | 1975 |
Liver function and gastric acid secretion in parkinsonian patients under prolonged treatment with L-dopa and a peripheral decarboxylase inhibitor.
Topics: Aged; Benserazide; Biopsy; Drug Combinations; Gastric Juice; Humans; Hydrazines; Levodopa; Liver; Liver Function Tests; Male; Middle Aged | 1976 |
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
Topics: Animals; Atropine; Benserazide; Blood Pressure; Carbidopa; Dogs; Dopamine; Drug Interactions; Female; Levodopa; Male; Monoamine Oxidase Inhibitors; Norepinephrine; Phentolamine; Pressoreceptors; Propranolol; Vagus Nerve | 1976 |
Coordinated stepping of all four limbs in the high spinal cat.
Topics: Animals; Benserazide; Cats; Electrophysiology; Extremities; Levodopa; Locomotion; Muscles; Nialamide; Spinal Cord | 1976 |
[The effect of stimulation and blockade of the dopaminergic system on the choice of behavioral strategy by rats in the shuttle box].
Topics: Animals; Benserazide; Brain; Choice Behavior; Drug Combinations; Haloperidol; Levodopa; Male; Physical Stimulation; Rats; Reaction Time; Receptors, Dopamine; Stress, Psychological | 1992 |
Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism.
Topics: Adult; Benserazide; Drug Combinations; Female; Hemiplegia; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Reflex, Abnormal; Syndrome | 1992 |
Muscle stiffness and continuous electromyographic activity in old rats; an animal model for spasticity?
Topics: Aging; Animals; Atrophy; Baclofen; Benserazide; Drug Combinations; Electromyography; Female; Levodopa; Muscle Contraction; Muscle Denervation; Muscle Spasticity; Muscle Tonus; Muscles; Rats; Rats, Wistar | 1992 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
Topics: Adult; Age Factors; Benserazide; Biomarkers; Biopterins; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Topics: Administration, Oral; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Caudate Nucleus; Dopamine; Drug Interactions; Extracellular Space; Levodopa; Male; Nitrophenols; Osmolar Concentration; Rats; Rats, Inbred Strains; Tetrodotoxin; Tolcapone | 1992 |
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Topics: Adult; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time | 1992 |
Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
Topics: Anti-Anxiety Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Myoclonus; Restless Legs Syndrome; Sleep Initiation and Maintenance Disorders; Sleep Stages; Somnambulism; Triazolam | 1991 |
Modulation by dopamine of [3H]N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine ([3H]BTCP, a phencyclidine derivative) binding to the dopamine uptake complex.
Topics: alpha-Methyltyrosine; Animals; Benserazide; Cocaine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Haloperidol; In Vitro Techniques; Levodopa; Male; Membrane Proteins; Methyltyrosines; Mice; Nerve Tissue Proteins; Phencyclidine; Piperazines; Rats; Reserpine | 1991 |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Somatostatin | 1990 |
Effect of L-dopa loading on 5-HTP decarboxylation in rat brain areas.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Corpus Striatum; Decarboxylation; Hippocampus; Hydroxyindoleacetic Acid; Hypothalamus; Levodopa; Male; Olfactory Bulb; Rats; Rats, Inbred Strains; Serotonin | 1991 |
Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
Topics: Adult; Basal Ganglia; Benserazide; Brain; Carbon Radioisotopes; Caudate Nucleus; Cerebellum; Cerebral Cortex; Frontal Lobe; Globus Pallidus; Humans; Levodopa; Ligands; Male; Models, Biological; Putamen; Tomography, Emission-Computed | 1991 |
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
Topics: Animals; Benserazide; Benzazepines; Corpus Striatum; Drug Administration Schedule; Hydroxydopamines; Levodopa; Male; Microscopy, Fluorescence; Myelin Sheath; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1 | 1991 |
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 1991 |
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Topics: Animals; Benserazide; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone; Tomography, Emission-Computed | 1991 |
Effect of L-dopa administration on islet monoamine oxidase activity and glucose-induced insulin release in the mouse.
Topics: Animals; Benserazide; Female; Glucose; Injections, Intravenous; Insulin; Islets of Langerhans; Levodopa; Mice; Monoamine Oxidase; Pancreas | 1991 |
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.
Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline | 1991 |
Biochemical and neurophysiological investigations in two forms of Segawa's disease.
Topics: Adolescent; Basal Ganglia Diseases; Benserazide; Diagnosis, Differential; Dystonia; Evoked Potentials; Female; Humans; Levodopa; Male; Syndrome; Tyrosine 3-Monooxygenase | 1990 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benserazide; Bromocriptine; Child; Dopamine Agents; Drug Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nausea; Restless Legs Syndrome; Time Factors | 1990 |
Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Benserazide; Biopterins; Brain; Dopamine; Female; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Saimiri; Time Factors; Tissue Distribution; Tyrosine 3-Monooxygenase | 1990 |
Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Topics: Adult; Autonomic Nervous System Diseases; Benserazide; Delayed-Action Preparations; Drug Combinations; Fever; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease | 1991 |
The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain.
Topics: Administration, Oral; Animals; Benserazide; Brain; Dopamine; Immunohistochemistry; Levodopa; Neurons; Raphe Nuclei; Rats; Rats, Inbred Strains; Serotonin; Thalamus | 1991 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
Topics: Animals; Benserazide; Benzophenones; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Electrochemistry; Erythrocytes; Half-Life; In Vitro Techniques; Levodopa; Male; Nitrophenols; Norepinephrine; Rats; Rats, Inbred Strains; Tolcapone; Tyrosine | 1990 |
Cognitive deficiency induced by the acute stress in rats: a possible role of brain catecholaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain Chemistry; Cognition Disorders; Dihydroxyphenylalanine; Escape Reaction; Exploratory Behavior; Levodopa; Male; Norepinephrine; Rats; Stress, Physiological | 1990 |
The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.
Topics: Animals; Benserazide; Brain Chemistry; Catecholamines; Chromatography, High Pressure Liquid; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Electrochemistry; Half-Life; Injections, Intraperitoneal; Levodopa; Male; Rats | 1990 |
Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Serotonin | 1990 |
Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Corpus Striatum; Dextroamphetamine; Dialysis; Dopamine; Extracellular Space; Kainic Acid; Levodopa; Male; Pargyline; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Synapses; Synaptic Transmission | 1990 |
Correlation between carbohydrate and catecholamine level impairments in methionine sulfoximine epileptogenic rat brain.
Topics: Animals; Benserazide; Brain; Carbohydrate Metabolism; Catecholamines; Dopamine; Dose-Response Relationship, Drug; Epilepsy; Glucose; Glycogen; Levodopa; Male; Methionine Sulfoximine; Norepinephrine; Rats; Rats, Inbred Strains | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects.
Topics: Adult; Benserazide; Dopamine; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; Levodopa; Male; Stereoisomerism | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
Topics: Aged; Aged, 80 and over; Benserazide; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; Levodopa; Male; Middle Aged; Parkinson Disease; Stereoisomerism | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1989 |
[The problems of L-dopa therapy in the course of Parkinson syndrome].
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1989 |
Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Topics: Aged; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carboxy-Lyases; Drug Combinations; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Pregnancy and parkinsonism. A case report without problem.
Topics: Adult; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Phenytoin; Time Factors; Tyrosine | 1989 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Madopar HBS and the decompensated phase of Parkinson disease.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.
Topics: Aged; Antipsychotic Agents; Benserazide; Bromocriptine; Clozapine; Delusions; Dibenzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hallucinations; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Tryptophan | 1985 |
Re-evaluation of the L-dopa loading effect on dopamine metabolism in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Therapy, Combination; Homovanillic Acid; Levodopa; Male; Rats; Rats, Inbred Strains; Tyrosine | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotic Disorders; Trihexyphenidyl | 1988 |
Optimization of symptomatic therapy in Parkinson's disease.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Computer-Assisted; Humans; Hydrazines; Levodopa; Models, Biological; Parkinson Disease; Reaction Time; Therapy, Computer-Assisted | 1989 |
Nicotinic acid or N-methyl nicotinamide prolongs elevated brain dopa and dopamine in L-dopa treatment.
Topics: Animals; Benserazide; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Levodopa; Liver; Male; Niacinamide; Nicotinic Acids; Rats; Rats, Inbred Strains; S-Adenosylmethionine | 1986 |
[An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
Topics: Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Stress by restraining potentiates morphine catalepsy in rats.
Topics: 5,6-Dihydroxytryptamine; Animals; Benserazide; Catalepsy; Diclofenac; Ditiocarb; Drug Interactions; Fenclonine; Hemicholinium 3; Levodopa; Male; Mefenamic Acid; Morphine; Naloxone; Rats; Rats, Inbred Strains; Restraint, Physical; Stress, Physiological | 1985 |
Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
Topics: Adult; Aged; Benserazide; Dopamine; Drug Combinations; Female; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary-Adrenal System; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Effects of 5-hydroxytryptamine, dopamine, and aromatic L-amino acids on growth hormone (GH)-releasing factor-stimulated GH release in rat anterior pituitaries.
Topics: Animals; Benserazide; Carbidopa; Dopamine; Growth Hormone; Growth Hormone-Releasing Hormone; In Vitro Techniques; Kinetics; Levodopa; Male; Pituitary Gland, Anterior; Rats; Rats, Inbred Strains; Serotonin; Tyrosine | 1987 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Topics: Administration, Oral; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Carbidopa; Delayed-Action Preparations; Dihydroxyphenylalanine; Dogs; Dopa Decarboxylase; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Kidney; Levodopa; Liver; Male; Mice; Rats; Time Factors; Tyrosine | 1987 |
L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Psychological Tests; Retrospective Studies | 1988 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1988 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1988 |
[Effect of L-dihydroxyphenylalanine on rat behavior and on catecholamine metabolism of the brain in rats with different degrees of emotional-behavioral reactivity].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Benserazide; Brain; Brain Chemistry; Catecholamines; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Emotions; Levodopa; Male; Rats | 1988 |
Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1987 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Topics: Adult; Antacids; Benserazide; Biological Availability; Delayed-Action Preparations; Drug Combinations; Eating; Gastric Mucosa; Humans; Hydrazines; Levodopa; Middle Aged; Stomach; Tyrosine | 1987 |
Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Topics: Administration, Oral; Adult; Benserazide; Biological Availability; Capsules; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Middle Aged | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors.
Topics: Animals; Behavior, Animal; Benserazide; Bromocriptine; Corpus Striatum; Denervation; Female; In Vitro Techniques; Levodopa; Rats; Receptors, Dopamine; Spiperone | 1987 |
Dissociation of receptor sensitivity changes in rat perifornical hypothalamus: a role for dopaminergic receptors in amphetamine anorexic tolerance.
Topics: Amphetamine; Animals; Anorexia; Benserazide; Dextroamphetamine; Drug Tolerance; Eating; Feeding and Eating Disorders; Hypothalamus; Isoproterenol; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1987 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Exogenous l-dopa alters spiroperidol binding, in vivo, in the mouse striatum.
Topics: alpha-Methyltyrosine; Animals; Benserazide; Biological Transport; Butyrophenones; Cerebellum; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Levodopa; Methyltyrosines; Mice; Receptors, Dopamine; Reserpine; Spiperone | 1986 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Reduction in paradoxical sleep after L-dopa administration in rats.
Topics: Animals; Benserazide; Electroencephalography; Haloperidol; Injections, Intraperitoneal; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sleep Stages; Sleep, REM | 1986 |
Individual levodopa therapy in Parkinson's disease.
Topics: Benserazide; Chromatography, High Pressure Liquid; Drug Combinations; Gait; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1987 |
Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Catalepsy; Drug Therapy, Combination; Haloperidol; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred Strains; Receptors, Dopamine | 1985 |
Pharmacological activation of locomotor patterns in larval and adult frog spinal cords.
Topics: 2-Aminoadipic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Aspartic Acid; Benserazide; Clonidine; In Vitro Techniques; Larva; Levodopa; Locomotion; N-Methylaspartate; Nialamide; Rana catesbeiana; Rana pipiens; Spinal Cord | 1985 |
[L-dopa therapy of parkinson syndrome].
Topics: Benserazide; Biotransformation; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine | 1985 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benserazide; Benzazepines; Callitrichinae; Levodopa; Male; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Tremor | 1985 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Topics: Adult; Aged; Benserazide; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Life Expectancy; Longitudinal Studies; Male; Middle Aged; Models, Biological; Phenethylamines; Retrospective Studies; Selegiline | 1985 |
Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System; Benserazide; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Heart; Heart Rate; Humans; Hydrazines; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease | 1985 |
Opioids, dopamine, and restless legs syndrome.
Topics: Benserazide; Dopamine; Humans; Levodopa; Narcotics; Restless Legs Syndrome | 1985 |
[The L-dopa test in Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Drug Therapy, Combination; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Recurrence; Time Factors | 1985 |
Dopaminergic drugs improve human visual contrast sensitivity.
Topics: Adult; Benserazide; Form Perception; Humans; Hydrazines; Levodopa; Nomifensine; Pattern Recognition, Visual | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
[A case of L-dopa induced autoimmune hemolytic anemida].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Humans; Levodopa; Male; Parkinson Disease | 1985 |
Enhancement of noradrenaline turnover in rat brain by L-dopa.
Topics: Animals; Benserazide; Brain; Depression, Chemical; Disulfides; Dopamine beta-Hydroxylase; Drug Synergism; Imidazoles; Levodopa; Male; Norepinephrine; Piperazines; Rats; Stimulation, Chemical | 1974 |
Protriptyline induced inhibition of the in vivo 3H-noradrenaline synthesis from 3H-L-dopa in the rat brain.
Topics: Animals; Antidepressive Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Brain Chemistry; Catecholamines; Cerebral Ventricles; Chromatography, Ion Exchange; Dibenzocycloheptenes; Homovanillic Acid; Injections; Levodopa; Male; Norepinephrine; Propylamines; Rats; Specific Pathogen-Free Organisms; Spectrometry, Fluorescence; Time Factors; Tritium; Tyrosine | 1974 |
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzyl Compounds; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenols | 1974 |
Effects of L-dopa on the heterosexual copulatory behavior of male rats.
Topics: Animals; Benserazide; Consummatory Behavior; Depression, Chemical; Dose-Response Relationship, Drug; Drug Synergism; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Rats; Reaction Time; Sexual Behavior, Animal; Time Factors | 1974 |
The effects of L-dopa and alpha-methyldopa on reflexes and sympathetic nerve function.
Topics: Animals; Atropine; Barbiturates; Benserazide; Blood Pressure; Carbidopa; Carotid Arteries; Dogs; Electric Stimulation; Heart Rate; Hindlimb; Levodopa; Methyldopa; Monoamine Oxidase Inhibitors; Neurons; Perfusion; Posture; Reflex; Regional Blood Flow; Sympathetic Nervous System; Vagotomy; Vagus Nerve | 1974 |
Secretion of L-DOPA through the choroid plexus.
Topics: Animals; Benserazide; Biological Transport, Active; Blood-Brain Barrier; Choroid Plexus; Epithelial Cells; Epithelium; Female; Levodopa; Male; Microscopy, Fluorescence; Nialamide; Rats | 1974 |
[Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man].
Topics: Adolescent; Adrenal Cortex; Adrenal Glands; Adult; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Female; Humans; Hydrazines; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Pituitary-Adrenal Function Tests | 1974 |
[Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Form Perception; Humans; Intelligence Tests; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Perceptual Disorders; Problem Solving; Space Perception; Thinking; Visual Perception; Wechsler Scales | 1974 |
[Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease, Secondary; Time Factors | 1974 |
[The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
Topics: Benserazide; Drug Combinations; Drug Evaluation; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Mental Processes; Parkinson Disease; Psychological Tests | 1974 |
[Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
Topics: Benserazide; Dopamine; Endorphins; Humans; Hypothalamo-Hypophyseal System; Levodopa; Nerve Tissue Proteins; Parkinson Disease; Prolactin; Receptors, Dopamine; Synaptic Transmission; Thyrotropin; Thyrotropin-Releasing Hormone | 1984 |
Dopamine antagonist and agonist treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Benserazide; Benzimidazoles; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Sulpiride | 1980 |
[Catecholaminergic neuronal pathways in homeostatic control of blood circulating mass].
Topics: Adrenergic alpha-Antagonists; Animals; Benserazide; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Diuresis; Levodopa; Methyldopa; Phentolamine; Rats; Thirst | 1980 |
Central action of L-DOPA in blood pressure regulation and effect on catecholamine content in the frog, Xenopus laevis.
Topics: Animals; Benserazide; Blood Pressure; Brain; Carbidopa; Catecholamines; Dopamine; Female; Levodopa; Myocardium; Xenopus laevis | 1981 |
The effect of L-DOPA on blood pressure and catecholamine content in the brain and peripheral organs in the Atlantic cod, Gadus morhua.
Topics: Animals; Benserazide; Blood Pressure; Brain Chemistry; Carbidopa; Catecholamines; Dopamine; Fishes; Levodopa; Time Factors | 1981 |
Effects of antihistaminic drugs in tests for antidepressant action.
Topics: Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Benserazide; Body Temperature; Histamine H1 Antagonists; Levodopa; Male; Mice; Motor Activity; Rats; Rats, Inbred Strains; Reserpine | 1981 |
[Variation in the levels of biogenic amines in the central and peripheral nervous system of rats with portacaval anastomoses after the administration of levodopa].
Topics: Adrenal Glands; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Central Nervous System; Levodopa; Male; Nervous System; Neurotransmitter Agents; Portacaval Shunt, Surgical; Rats | 1982 |
Levodopa and receptor sensitivity modification in tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Receptors, Dopamine; Schizophrenia | 1982 |
Chronic L-DOPA-pretreatment of rats: an electrophysiological and biochemical study in the basal ganglia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Basal Ganglia; Benserazide; Corpus Striatum; Dextroamphetamine; Dopamine; Evoked Potentials; Homovanillic Acid; Levodopa; Male; Neurons; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase | 1982 |
Transneuronal regulation of tyrosine hydroxylase expression in olfactory bulb of mouse and rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Afferent Pathways; Animals; Benserazide; Dihydroxyphenylalanine; Dopamine; Female; Levodopa; Mice; Mice, Inbred Strains; Neurons; Norepinephrine; Olfactory Bulb; Rats; Rats, Inbred Strains; Reserpine; Species Specificity; Tyrosine 3-Monooxygenase | 1983 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-DOPA.
Topics: Animals; Apomorphine; Benserazide; Binding Sites; Cell Membrane; Corpus Striatum; Dopamine; Hydrazines; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Tetrahydronaphthalenes; Tyrosine 3-Monooxygenase | 1984 |
In vitro occurrence of m-octopamine in the cultured cephalic ganglion of Locusta migratoria L. after L-dopa administration.
Topics: Animals; Benserazide; Biogenic Amines; Catecholamines; Fusaric Acid; Ganglia; Grasshoppers; Head; Kinetics; Levodopa; Male; Octopamine; Organ Culture Techniques; Tyramine | 1984 |
The effects of phenylpropanolamine and other sympathomimetics on food consumption and motor activity in mice.
Topics: alpha-Methyltyrosine; Animals; Benserazide; Eating; Female; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Phenylpropanolamine; Sympathomimetics; Time Factors | 1984 |
Plasma catecholamines during activation of the sympathetic nervous system in a patient with Shy-Drager syndrome.
Topics: Autonomic Nervous System Diseases; Benserazide; Catecholamines; Dopamine; Epinephrine; Female; Humans; Levodopa; Middle Aged; Norepinephrine; Physical Exertion; Posture; Shy-Drager Syndrome; Sympathetic Nervous System | 1980 |
[Effect of L-DOPA on brain serotonin metabolism related to tryptophan concentrations in plasma and brain of rats].
Topics: Animals; Benserazide; Brain; Brain Chemistry; Dopamine; Dose-Response Relationship, Drug; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Levodopa; Male; Rats; Rats, Inbred Strains; Serotonin; Tryptophan | 1981 |
[Interactions of cerebral serotonin and catecholamines].
Topics: 5,7-Dihydroxytryptamine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Catecholamines; Dopamine; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Nerve Endings; Neurons; Norepinephrine; Rats; Serotonin; Tryptophan | 1983 |
Enhancement by the putative 5-HT receptor agonist 8-OH-2-(di-n-propylamino)tetralin of the acoustic startle response in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Benserazide; Levodopa; Male; Naphthalenes; Rats; Rats, Inbred Strains; Receptors, Histamine; Reflex, Startle; Serotonin; Tetrahydronaphthalenes | 1983 |
[Combined (surgical and drug) therapy of parkinsonism].
Topics: Benserazide; Catecholamines; Combined Modality Therapy; Diencephalon; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1984 |
Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase; Phenethylamines; Phenylacetates; Selegiline | 1983 |
Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
Topics: Aged; Benserazide; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Topics: Aged; Benserazide; Droxidopa; Gait; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Parkinson Disease; Serine | 1984 |
Mechanisms involved in the prolactin-releasing effect of benserazide.
Topics: Animals; Benserazide; Binding, Competitive; Dopamine; Female; Hydrazines; In Vitro Techniques; Levodopa; Male; Median Eminence; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone | 1984 |
Combined use of benserazide and carbidopa in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease | 1984 |
Effects of imipramine on behavior and brain norepinephrine metabolism in tetrabenazine treated rats: comparative study of a single administration with repeated administrations of imipramine.
Topics: alpha-Methyltyrosine; Animals; Benserazide; Brain Chemistry; Drug Interactions; Glycols; Imipramine; Levodopa; Male; Methoxyhydroxyphenylglycol; Methyltyrosines; Rats; Rats, Inbred Strains; Tetrabenazine | 1983 |
Dystonia--L-dopa responsive or juvenile parkinsonism?
Topics: Adolescent; Benserazide; Carbidopa; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Follow-Up Studies; Growth Hormone; Humans; Infant; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Intestinal absorption of levodopa in man.
Topics: Adult; Benserazide; Electrocardiography; Humans; Intestinal Absorption; Levodopa; Male; Smoking | 1983 |
[Exploration of the tubero-hypophyseal dopaminergic system in patients with chronic parkinsonism during chronic treatment with L-DOPA].
Topics: Aged; Benserazide; Blood-Brain Barrier; Humans; Hypothalamo-Hypophyseal System; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
Topics: Benserazide; Bromocriptine; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sexual Dysfunction, Physiological | 1983 |
Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.
Topics: Animals; Apomorphine; Benserazide; Humans; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Rats; Receptors, Dopamine; Reserpine; Stereotyped Behavior | 1983 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1984 |
Upper airway obstruction complicating the Shy-Drager syndrome.
Topics: Adult; Airway Obstruction; Autonomic Nervous System Diseases; Benserazide; Double-Blind Method; Humans; Levodopa; Male; Shy-Drager Syndrome; Tidal Volume | 1984 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
Modification of mouse islet function by 5-hydroxytryptamine, dopamine and their precursors.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Calcium; Dopamine; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Levodopa; Mice; Mice, Inbred Strains; Serotonin | 1982 |
Subacute L-DOPA in mice: biochemical and behavioural effects.
Topics: Animals; Behavior, Animal; Benserazide; Brain Chemistry; Kinetics; Levodopa; Male; Mice; Motor Activity; Receptors, Dopamine; Stereoisomerism | 1980 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Long-term responses of Parkinson's disease to levodopa therapy.
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease | 1980 |
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.
Topics: Animals; Apomorphine; Benserazide; Body Temperature Regulation; Brain; Clonidine; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Male; Mice; Motor Activity; Norepinephrine; Substance Withdrawal Syndrome | 1981 |
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Topics: Aged; Benserazide; Drug Combinations; Electromyography; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Thyrotropin; Thyrotropin-Releasing Hormone | 1980 |
Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide.
Topics: Benserazide; Drug Administration Schedule; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1982 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
A glimpse into Roche research: antiparkinson treatment.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Industry; History, 20th Century; Humans; Hydrazines; Levodopa; Male; Switzerland | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
The effect of L-dopa on pupillary diameter in mice.
Topics: Animals; Benserazide; Carbidopa; Fusaric Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Phentolamine; Pupil | 1982 |
Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide.
Topics: Acute Disease; Aged; Anemia; Antiparkinson Agents; Benserazide; Humans; Hydrazines; Levodopa; Male | 1982 |
In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues.
Topics: Amine Oxidase (Copper-Containing); Animals; Benserazide; Cardiovascular System; Clorgyline; Drug Resistance; Hydrazines; In Vitro Techniques; Kinetics; Levodopa; Male; Monoamine Oxidase; Oxidoreductases Acting on CH-NH Group Donors; Propylamines; Rats; Rats, Inbred Strains | 1982 |
Parkinsonism in the elderly.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease | 1982 |
Treatment of restless legs syndrome with levodopa plus benserazide.
Topics: Adult; Benserazide; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Restless Legs Syndrome | 1982 |
Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
Topics: Animals; Benserazide; Blood Pressure; Blood-Brain Barrier; Brain; Carbidopa; Catecholamines; Clonidine; Heart Rate; Hemodynamics; Levodopa; Lizards; Myocardium | 1982 |
New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Topics: Adult; Aged; Benserazide; Carbidopa; Choline; Cytidine Diphosphate Choline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
No evidence for a peripheral effect of L-DOPA on plasma prolactin in the rat.
Topics: Animals; Benserazide; Female; Lactation; Levodopa; Male; Pregnancy; Prolactin; Rats; Sheep | 1982 |
L-dopa competes with tyrosine and tryptophan for human brain uptake.
Topics: Aged; Benserazide; Blood-Brain Barrier; Brain; Female; Humans; Levodopa; Male; Parkinson Disease; Tryptophan; Tyrosine | 1980 |
L-dopa and benserazide in the treatment of acute hepatic encephalopathy in infancy.
Topics: Acute Disease; Benserazide; Female; Hepatic Encephalopathy; Humans; Hydrazines; Infant; Levodopa | 1980 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine | 1981 |
Central action of ketotifen.
Topics: Amphetamine; Animals; Benserazide; Brain; Drug Interactions; Ketotifen; Lethal Dose 50; Levodopa; Male; Mice; Motor Activity; Rats; Rats, Inbred Strains; Reserpine | 1981 |
The influence of benserazide on changes in monoamine oxidase activity in some rat tissues following treatment with L-DOPA.
Topics: Animals; Benserazide; Benzylamines; Growth; Hydrazines; Kidney; Kinetics; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Myocardium; Rats; Rats, Inbred Strains; Serotonin | 1980 |
[Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
Topics: Adult; Benserazide; Electrocardiography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1980 |
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Topics: Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Cross-Sectional Studies; Dialysis; Drug Synergism; Enzyme Inhibitors; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease | 1995 |
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
[Multilevel neurochemical organization of the brain].
Topics: Animals; Benserazide; Brain Chemistry; Carboxy-Lyases; Chinchilla; Drug Combinations; Levodopa; Neurochemistry; Rats; Rats, Wistar | 1994 |
[The protective action of adaptation to hypoxia in audiogenic epilepsy and its prolongation by using pharmacologic agents].
Topics: Acoustic Stimulation; Adaptation, Physiological; Animals; Benserazide; Brain; Brain Chemistry; Drug Combinations; Hypoxia; Levodopa; Male; Neurons; Orotic Acid; Rats; Rats, Inbred Strains; RNA; Seizures; Time Factors | 1994 |
Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
Topics: Administration, Oral; Aged; Benserazide; Bromocriptine; Deglutition; Deglutition Disorders; Drug Administration Schedule; Eating; Humans; Levodopa; Male; Parkinson Disease | 1995 |
Intrarenal dopamine participation in frusemide diuretic and natriuretic responses to frusemide.
Topics: Animals; Benserazide; Creatinine; Diuresis; Dopamine; Furosemide; Glomerular Filtration Rate; Glucose; In Vitro Techniques; Kidney; Levodopa; Male; Natriuresis; Photometry; Rats; Rats, Wistar | 1995 |
Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Topics: Animals; Benserazide; Benzophenones; Biotransformation; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Half-Life; Injections, Intravenous; Levodopa; Male; Methylation; Nitrophenols; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tissue Distribution; Tolcapone | 1995 |
Effects of palmatine on motor activity and the concentration of central monoamines and its metabolites in rats.
Topics: 5-Hydroxytryptophan; alpha-Methyltyrosine; Animals; Benserazide; Berberine Alkaloids; Brain; Brain Stem; Cerebral Cortex; Dopamine; Drug Interactions; Fenclonine; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Methyltyrosines; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin | 1993 |
Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Homovanillic Acid; Levodopa; Male; Methylation; Microdialysis; Neostriatum; Nitrophenols; Rats; Tolcapone | 1995 |
Effect of type A and B monoamine oxidase selective inhibition by Ro 41-1049 and Ro 19-6327 on dopamine outflow in rat kidney slices.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Dopamine; In Vitro Techniques; Isoenzymes; Kidney Cortex; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Picolinic Acids; Rats; Rats, Wistar; Thiazoles | 1994 |
[Pathochemical changes in the motor structures of the brain under the influence of the administration of L-DOPA preparations and their withdrawal (experimental research)].
Topics: Animals; Benserazide; Brain; Brain Chemistry; Drug Combinations; Histocytochemistry; Levodopa; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Time Factors | 1994 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Nomifensine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrodotoxin | 1994 |
[Tumoral Parkinson hemi-syndrome sensitive to L-dopa].
Topics: Benserazide; Brain Neoplasms; Drug Therapy, Combination; Glioblastoma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors | 1994 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Synergism; Haloperidol; Kinetics; Levodopa; Male; Mice; Mice, Inbred C57BL; Nitrophenols; Tolcapone; Tyrosine | 1994 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Topics: Adenosine; Administration, Oral; Animals; Antihypertensive Agents; Benserazide; Catalepsy; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Levodopa; Male; Mice; Phenethylamines; Purinergic Antagonists; Xanthines | 1994 |
Meperidine and reversible parkinsonism.
Topics: Adult; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Meperidine; Neurologic Examination; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1994 |
[Segawa's disease: progressive dystonia responsive to L-dopa. A case report].
Topics: Adult; Benserazide; Diagnosis, Differential; Dystonia; Female; Humans; Levodopa; Neurologic Examination | 1993 |
Cografts of adrenal medulla with peripheral nerve for Parkinson's disease.
Topics: Adrenal Medulla; Adrenalectomy; Adult; Benserazide; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Humans; Levodopa; Parkinson Disease; Peripheral Nerves; Time Factors; Transplantation, Autologous | 1994 |
3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Topics: Animals; Benserazide; Catalepsy; Drug Combinations; Haloperidol; Levodopa; Male; Mice; Motor Activity; Tyrosine | 1994 |
[Restless legs syndrome. Report of experience].
Topics: Benserazide; Codeine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Restless Legs Syndrome | 1993 |
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychotic Disorders | 1993 |
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Topics: Aged; Benserazide; Biogenic Monoamines; China; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
Parkinson's disease study.
Topics: Benserazide; Bias; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1993 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Tremor | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Topics: Animals; Benserazide; Benzophenones; Brain; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Homovanillic Acid; Humans; Levodopa; Male; Nitrophenols; Peripheral Nerves; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Tolcapone | 1993 |
Involvement of renal dopamine synthesis in the diuretic effect of furosemide in normohydrated rats.
Topics: Animals; Benserazide; Diuresis; Dopamine; Female; Furosemide; Kidney; Levodopa; Rats; Rats, Wistar; Receptors, Dopamine D1; Sodium | 1993 |
The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.
Topics: Adult; Antipyrine; Benserazide; Female; Glucose; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestine, Small; Jejunum; Leucine; Levodopa; Male; Perfusion; Stereoisomerism | 1993 |
Locally formed dopamine modulates renal Na-Pi co-transport through DA1 and DA2 receptors.
Topics: Adenylate Cyclase Toxin; Animals; Benserazide; Bromocriptine; Calcium; Carbidopa; Carrier Proteins; Cell Line; Cyclic AMP; Dopamine; Kidney Tubules, Proximal; Kinetics; Levodopa; Opossums; Parathyroid Hormone; Pertussis Toxin; Phosphates; Receptors, Dopamine D1; Receptors, Dopamine D2; Sodium; Sodium-Phosphate Cotransporter Proteins; Symporters; Virulence Factors, Bordetella | 1995 |
Treatment of Parkinson's disease in a patient with acute intermittent porphyria.
Topics: Aged; Antiparkinson Agents; Benserazide; Chlorpromazine; Dopamine Antagonists; Drug Interactions; Female; Humans; Levodopa; Parkinson Disease; Porphyria, Acute Intermittent; Trihexyphenidyl | 1995 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Effects of Hemerocallis flava on motor activity and the concentration of central monoamines and its metabolites in rats.
Topics: 5-Hydroxytryptophan; alpha-Methyltyrosine; Amines; Analysis of Variance; Animals; Benserazide; Brain Stem; Cerebral Cortex; Dopamine; Dopamine Agents; Enzyme Inhibitors; Fenclonine; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Mandelic Acids; Methyltyrosines; Motor Activity; Norepinephrine; Plant Extracts; Plants, Medicinal; Rats; Serotonin; Serotonin Agents | 1996 |
Motor effects of lamotrigine in naive and dopamine-depleted mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Uptake Inhibitors; Animals; Anticonvulsants; Antiparkinson Agents; Benserazide; Depression, Chemical; Dopamine; Dopamine Agonists; Gait; Lamotrigine; Levodopa; Male; Mice; Mice, Inbred Strains; Motor Activity; Phenethylamines; Posture; Receptors, Dopamine D1; Receptors, Dopamine D2; Reserpine; Triazines | 1996 |
The depletion of brain serotonin levels by para-chlorophenylalanine administration significantly alters the activity of midbrain dopamine cells in rats: an extracellular single cell recording study.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain Chemistry; Dopamine; Dopamine Agents; Electrophysiology; Extracellular Space; Fenclonine; Levodopa; Male; Mechanoreceptors; Mesencephalon; Rats; Rats, Sprague-Dawley; Serotonin Agents; Substantia Nigra; Ventral Tegmental Area | 1996 |
In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benserazide; Brain Chemistry; Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Drug Interactions; Electrochemistry; Homovanillic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Microdialysis; Neostriatum; Rats; Rats, Wistar | 1996 |
Behavioral and neurochemical effects induced by chronic L-DOPA administration.
Topics: Acetylcholine; Animals; Behavior, Animal; Benserazide; Dose-Response Relationship, Drug; Hippocampus; Levodopa; Male; Maze Learning; Rats; Time Factors; Tissue Distribution | 1996 |
Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes.
Topics: Adult; alpha-Methyltyrosine; Aromatic Amino Acid Decarboxylase Inhibitors; B-Lymphocytes; Benserazide; Catecholamines; Chromatography, High Pressure Liquid; Disulfiram; Dopamine; Dopamine beta-Hydroxylase; Enzyme Inhibitors; Female; Fusaric Acid; Humans; Levodopa; Male; Methyltyrosines; Norepinephrine; T-Lymphocytes; Tyrosine; Tyrosine 3-Monooxygenase | 1996 |
Tyrosine and tryptophan derivatives in pig lumbar cerebrospinal fluid. Effects of subchronic administration of dopa associated with benserazide.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Benserazide; Drug Interactions; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Male; Methoxyhydroxyphenylglycol; Normetanephrine; Swine; Tryptamines; Tryptophan; Tyrosine | 1996 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benserazide; Drug Interactions; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Visual Cortex | 1997 |
6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study.
Topics: Adult; Alcohol Oxidoreductases; Antiparkinson Agents; Base Sequence; Benserazide; Circadian Rhythm; Drug Therapy, Combination; Dystonia; Female; Homozygote; Humans; Levodopa; Molecular Sequence Data; Phosphorus-Oxygen Lyases; Point Mutation; Polymerase Chain Reaction; Pterins | 1997 |
Apical and basal uptake of L-dopa and L-5-HTP and their corresponding amines, dopamine and 5-HT, in OK cells.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Biological Transport; Cell Polarity; Cells, Cultured; Dopamine; Female; Kidney; Kinetics; Levodopa; Opossums; Serotonin; Water; Water-Electrolyte Balance | 1997 |
Swallowing difficulty in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Barium Sulfate; Benserazide; Contrast Media; Deglutition Disorders; Drug Therapy, Combination; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Oropharynx; Parkinson Disease; Videotape Recording | 1997 |
[L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
Topics: Adult; Animals; Antiparkinson Agents; Benserazide; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Pregnancy; Pregnancy Complications; Rabbits | 1997 |
Nonneuronal dopamine.
Topics: Adrenergic alpha-Agonists; Amiloride; Animals; Benserazide; Biological Transport; Brimonidine Tartrate; Catechol O-Methyltransferase; Dopamine; Kidney; Kidney Cortex; Kidney Tubules; Levodopa; Models, Biological; Monoamine Oxidase; Phenylephrine; Quinoxalines; Sodium-Hydrogen Exchangers | 1998 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Topics: Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Metabolism; Benserazide; Dopamine; Dopamine Agents; Enzyme Inhibitors; Injections, Intraperitoneal; Levodopa; Male; Neostriatum; Premedication; Rats; Rats, Wistar | 1997 |
Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benserazide; Body Water; Calcium Channel Blockers; Cell Survival; Cyclosporine; Decarboxylation; Dopamine; Dopamine Agents; Levodopa; LLC-PK1 Cells; Swine; Verapamil | 1998 |
Apical and basolateral uptake and intracellular fate of dopamine precursor L-dopa in LLC-PK1 cells.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Biological Transport; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Enzyme Inhibitors; Epithelial Cells; Kidney Tubules, Proximal; Kinetics; Levodopa; LLC-PK1 Cells; Piperazines; Swine | 1998 |
Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Cell Nucleus; Corpus Striatum; Denervation; Dizocilpine Maleate; Gene Expression Regulation; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Transcription Factor AP-1 | 1997 |
[Madopar: more than 20 years].
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; History, 20th Century; Humans; Levodopa; Parkinson Disease | 1997 |
L-DOPA exacerbates amphetamine-induced dopamine depletion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Chromatography, High Pressure Liquid; Corpus Striatum; Dextroamphetamine; Dopamine; Drug Synergism; Frontal Lobe; Hippocampus; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Mice; Organ Specificity; Serotonin | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Benserazide; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Thalamic Nuclei | 1998 |
Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Biological Transport; Caco-2 Cells; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dihydroxyphenylalanine; Dopamine; Humans; Intestinal Mucosa; Kinetics; Levodopa | 1998 |
Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1998 |
Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis.
Topics: Acute Disease; Adult; Antiparkinson Agents; Benserazide; Cystic Fibrosis; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Pons | 1999 |
Neurotoxic effects of amphetamine plus L-DOPA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Corpus Striatum; Dextroamphetamine; Dopamine; Drug Interactions; Frontal Lobe; Homovanillic Acid; Hypothalamus; Levodopa; Male; Mice; Neurons; Neurotoxins; Organ Specificity; Serotonin; Time Factors | 1999 |
L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma.
Topics: Aged; Antiparkinson Agents; Benserazide; Female; Humans; Levodopa; Male; Melanoma; Microdialysis; Middle Aged; Parkinson Disease; Skin Neoplasms | 1999 |
Buprenorphine potentiates L-DOPA-induced contralateral rotation in 6-hydroxydopamine-treated rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Benserazide; Buprenorphine; Drug Synergism; Injections, Intraventricular; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Opioid | 1999 |
L-DOPS-Accelerated recovery of locomotor function in rats subjected to sensorimotor cortex ablation injury: pharmacobehavioral studies.
Topics: Animals; Benserazide; Brain; Cerebral Cortex; Dopamine Agents; Droxidopa; Drug Therapy, Combination; Levodopa; Male; Methoxyhydroxyphenylglycol; Motor Activity; Norepinephrine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Stroke | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders | 2000 |
Influence of dopaminergic anti-Parkinsonian agents on inflammatory reactions in rats.
Topics: Animals; Antiparkinson Agents; Arthritis, Experimental; Benserazide; Bromocriptine; Carrageenan; Dopamine Agents; Edema; Evans Blue; Female; Inflammation; Levodopa; Rats; Rats, Wistar | 2000 |
Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis.
Topics: Benserazide; Carbidopa; Electrophoresis, Capillary; Levodopa; Molecular Structure; Quality Control | 2000 |
Occupational Mn parkinsonism: magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation.
Topics: Antiparkinson Agents; Benserazide; Brain; Chelating Agents; Edetic Acid; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Manganese Poisoning; Metals, Heavy; Middle Aged; Occupational Diseases; Occupational Exposure; Parkinsonian Disorders | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2 | 2001 |
[A case of delusional jealousy in Parkinson disease ].
Topics: Antiparkinson Agents; Benserazide; Delusions; Dose-Response Relationship, Drug; Drug Combinations; Humans; Jealousy; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Parkinsonism after glycine-derivate exposure.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Globus Pallidus; Glycine; Glyphosate; Herbicides; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease, Secondary; Substantia Nigra; Videotape Recording | 2001 |
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Decarboxylation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Levodopa; Male; Microdialysis; Neostriatum; Parkinson Disease; Rats; Rats, Wistar | 2001 |
A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping.
Topics: Alleles; Amino Acid Sequence; Aromatic Amino Acid Decarboxylase Inhibitors; Base Sequence; Benserazide; Biopterins; Cells, Cultured; Child, Preschool; Dihydroxyphenylalanine; Drug Combinations; Dystonia; Enzyme Inhibitors; Exons; Female; Fibroblasts; GTP Cyclohydrolase; Humans; Introns; Levodopa; Male; Mutation; Neopterin; RNA Splicing; RNA, Messenger | 2001 |
A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
Topics: Algorithms; Animals; Antiparkinson Agents; Benserazide; Calibration; Carboxy-Lyases; Drug Interactions; Injections, Intravenous; Levodopa; Male; Models, Biological; Rats; Rats, Wistar | 2001 |
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Binding Sites; Carbidopa; Crystallography, X-Ray; Dopa Decarboxylase; Drug Design; Humans; Kidney; Levodopa; Ligands; Models, Molecular; Parkinson Disease; Pliability; Protein Structure, Secondary; Swine | 2001 |
L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Avoidance Learning; Benserazide; Biogenic Monoamines; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Male; Memory Disorders; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2001 |
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male; Parkinsonian Disorders | 2002 |
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Binding Sites; Binding, Competitive; Brain; Carbidopa; Clonidine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Enzyme Inhibitors; Female; Isoquinolines; Kinetics; Lactation; Levodopa; Male; Mazindol; Median Eminence; Methyldopa; Pituitary Gland; Pituitary Gland, Posterior; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reserpine | 2003 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug | 2002 |
Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Canada; Caregivers; Cost Savings; Dopamine Agonists; Drug Costs; Health Care Costs; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Treatment Outcome | 2003 |
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; N-Methylaspartate; Neuronal Plasticity; Parkinsonian Disorders; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptosomes | 2003 |
Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Cocaine; Denervation; Dopamine; Dopamine Uptake Inhibitors; Enkephalins; Enzyme Inhibitors; Female; Hydroxydopamines; Immunohistochemistry; In Situ Hybridization; Levodopa; Neostriatum; Neural Pathways; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympathectomy, Chemical | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2003 |
Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amantadine; Analysis of Variance; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2003 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Homovanillic Acid; Levodopa; Male; Mice; Parkinson Disease, Secondary; Plant Extracts; Plants, Medicinal; Reserpine | 2002 |
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Topics: Acetophenones; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Corpus Striatum; Dihydroxyphenylalanine; Drug Interactions; Erythrocytes; Humans; In Vitro Techniques; Levodopa; Liver; Methylation; Methyldopa; Microdialysis; Rats; Rats, Wistar | 2003 |
A case report of dopa-responsive dystonia.
Topics: Adolescent; Antiparkinson Agents; Benserazide; Drug Combinations; Dystonia; Humans; Levodopa; Male | 2001 |
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benserazide; Case-Control Studies; Dyskinesias; Female; Half-Life; Humans; Levodopa; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Sex Characteristics | 2003 |
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes | 2003 |
Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Benserazide; Brain Chemistry; Caffeine; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Microdialysis; Rats; Rats, Wistar; Reserpine | 2004 |
Gas chromatography/mass spectrometric identification of dopaminergic metabolites in striata of rats treated with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine Agents; Drug Therapy, Combination; Gas Chromatography-Mass Spectrometry; Injections, Intraperitoneal; Levodopa; Male; Rats; Rats, Sprague-Dawley | 2004 |
Parkinsonism following anterior choroidal artery stroke.
Topics: Adult; Angiography; Antiparkinson Agents; Benserazide; Cerebral Infarction; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinsonian Disorders; Putamen; Tomography, Emission-Computed, Single-Photon | 2004 |
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dopamine; Drug Synergism; Electron Transport Complex I; Levodopa; Male; Motor Activity; Motor Skills; Muscle Rigidity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2004 |
Antinociceptive mechanism of L-DOPA.
Topics: Animals; Behavior, Animal; Benserazide; Benzazepines; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Injections, Spinal; Levodopa; Male; Mice; Pain; Pain Measurement; Spinal Cord; Substance P; Time Factors | 2004 |
Simultaneous determination of levodopa and benserazide by stopped-flow injection analysis and three-way multivariate calibration of kinetic-spectrophotometric data.
Topics: Benserazide; Chromatography, High Pressure Liquid; Flow Injection Analysis; Levodopa; Multivariate Analysis; Spectrophotometry, Ultraviolet | 2004 |
[What helps in the treatment of restless legs?].
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Restless Legs Syndrome; Treatment Outcome | 2004 |
[Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice].
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Time Factors; Treatment Outcome | 2004 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Ataxia; Benserazide; Blindness; Corpus Striatum; Dopamine; Homeodomain Proteins; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Psychomotor Performance; Substantia Nigra; Transcription Factors | 2005 |
[Influence of L-DOPA on rat brain depending on individual behavioral features].
Topics: Animals; Behavior, Animal; Benserazide; Brain; Caudate Nucleus; Dopamine Agents; Drug Combinations; Hippocampus; Levodopa; Male; Motor Activity; Motor Cortex; Nucleus Accumbens; Rats; Rats, Inbred Strains; Rats, Wistar; Stress, Psychological; Time Factors | 2004 |
Cholinopositive effect of dilept (neurotensin peptidomimetic) as the basis of its mnemotropic effect.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Benserazide; Drug Combinations; Levodopa; Male; Memory; Mice; Mice, Inbred Strains; Muscarinic Antagonists; Neurotensin; Olfactory Bulb; Peptides; Rats; Rats, Wistar; Receptors, Muscarinic; Schizophrenia; Scopolamine; Space Perception | 2005 |
Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Topics: Analysis of Variance; Animals; Avoidance Learning; Benserazide; Catalepsy; Dopamine; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Levodopa; Male; Microdialysis; Nucleus Accumbens; Prefrontal Cortex; Raclopride; Rats; Rats, Wistar; Time Factors | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
A spectroscopic study on applicability of spectral analysis for simultaneous quantification of l-dopa, benserazide and ascorbic acid in batch and flow systems.
Topics: Ascorbic Acid; Benserazide; Calibration; Levodopa; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2005 |
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Paraphilic Disorders; Parkinson Disease; Pedophilia; Pergolide | 2006 |
L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Cell Count; Central Nervous System; Dopamine Agents; Drug Interactions; Enzyme Inhibitors; Functional Laterality; Gene Expression Regulation; Hydrazines; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2006 |
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benserazide; Cohort Studies; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain Measurement; Polysomnography; Predictive Value of Tests; Restless Legs Syndrome | 2006 |
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Agents; Drug Resistance; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neural Pathways; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D3; Receptors, Steroid; Transcription Factors | 2006 |
Simultaneous determination of benserazide and levodopa by capillary electrophoresis-chemiluminescence using an improved interface.
Topics: Benserazide; Electrophoresis, Capillary; Levodopa; Luminescent Measurements; Reproducibility of Results | 2006 |
Evaluation of an osmotic pump for microdialysis sampling in an awake and untethered rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain Chemistry; Dopamine; Extracellular Fluid; Homovanillic Acid; Hydroxyindoleacetic Acid; Infusion Pumps; Levodopa; Male; Microdialysis; Neurochemistry; Neurotransmitter Agents; Osmotic Pressure; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation; Wakefulness | 2007 |
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, AMPA; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; Treatment Outcome | 2007 |
Delayed L-DOPA-induced hyperalgesia.
Topics: Animals; Benserazide; Benzazepines; Hyperalgesia; Levodopa; Male; Mice; Quinpirole; Receptors, Dopamine D2 | 2006 |
Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.
Topics: Adult; Benserazide; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Levodopa; Multiple Sclerosis; Restless Legs Syndrome | 2007 |
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Infusions, Intravenous; Levodopa; Locomotion; Male; Motor Activity; MSH Release-Inhibiting Hormone; Parkinsonian Disorders | 2007 |
Continuous wavelet and derivative transforms for the simultaneous quantitative analysis and dissolution test of levodopa-benserazide tablets.
Topics: Algorithms; Antiparkinson Agents; Benserazide; Drug Combinations; Indicators and Reagents; Levodopa; Reference Standards; Solubility; Spectrophotometry, Ultraviolet; Tablets | 2007 |
Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Cerebrovascular Circulation; Drug Synergism; Exercise Therapy; Exercise Tolerance; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Hypothalamus; Levodopa; Male; Middle Aged; Parkinson Disease; Physical Exertion; Pituitary Gland, Anterior | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar | 2008 |
[Isolated pulmonary hypertension and pergolide].
Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiography; Humans; Hypertension, Pulmonary; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease, Postencephalitic; Pergolide; Pramipexole | 2008 |
Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.
Topics: Antiparkinson Agents; Antiviral Agents; Benserazide; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-alpha; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families.
Topics: Adolescent; Adult; Aged; Asian People; Benserazide; Child; Child, Preschool; Dopamine Agents; Drug Combinations; Dystonia; Female; Genetic Variation; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Mutation; Pedigree; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases; Young Adult | 2008 |
Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease.
Topics: Adipocytes; Adipose Tissue; Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Female; Glycerol; Humans; Isoproterenol; Levodopa; Male; Microdialysis; Middle Aged; Muscle, Skeletal; Parkinson Disease; Regional Blood Flow; Subcutaneous Fat | 2008 |
Simultaneous chemiluminometric determination of levodopa and benserazide in a multi-pumping flow system with multivariate calibration.
Topics: Antiparkinson Agents; Automation; Benserazide; Calibration; Flow Injection Analysis; Levodopa; Luminescent Measurements; Neural Networks, Computer; Pharmaceutical Preparations; Principal Component Analysis; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate | 2009 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Benserazide; Brain Injuries; Dihydroxyphenylalanine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Prazosin; Receptors, Adrenergic, alpha | 2009 |
Acute stepwise challenge test with levodopa in treated patients with parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Cohort Studies; Deep Brain Stimulation; Demography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Predictive Value of Tests; Prospective Studies; ROC Curve; Treatment Outcome | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics | 2009 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Catecholamine excess in a patient with restless legs syndrome treated with levodopa and benserazide.
Topics: Adult; Antiparkinson Agents; Benserazide; Catecholamines; Diagnosis, Differential; Drug Combinations; False Positive Reactions; Female; Humans; Hypertension; Levodopa; Restless Legs Syndrome | 2009 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benserazide; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Homovanillic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Rats; Rats, Wistar; Time Factors; Triazines; Triazoles; Xanthines | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; In Situ Hybridization; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Receptor, Cannabinoid, CB1; Severity of Illness Index | 2011 |
A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Drug Combinations; Feasibility Studies; Infusion Pumps; Intestinal Absorption; Intestinal Mucosa; Intestines; Levodopa; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2010 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Severe gastroparesis in a patient with advanced Parkinson's disease.
Topics: Aged, 80 and over; Benserazide; Dopamine Agents; Drug Combinations; Enzyme Inhibitors; Follow-Up Studies; Gastroparesis; Humans; Levodopa; Male; Parkinson Disease; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Complementary acupuncture treatment increases cerebral metabolism in patients with Parkinson's disease.
Topics: Acupuncture Therapy; Aged; Antiparkinson Agents; Benserazide; Brain Chemistry; Combined Modality Therapy; Drug Combinations; Energy Metabolism; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Increasing CNS noradrenaline reduces EAE severity.
Topics: Adrenergic Uptake Inhibitors; Animals; Astrocytes; Atomoxetine Hydrochloride; Benserazide; Benzylamines; Brain Chemistry; Central Nervous System; Cytokines; Dopamine Agents; Encephalomyelitis, Autoimmune, Experimental; Female; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Norepinephrine; Propylamines; T-Lymphocytes | 2010 |
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Callithrix; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Levodopa; Male; Methyldopa; Motor Activity; Movement Disorders | 2010 |
Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biotransformation; Catechol O-Methyltransferase Inhibitors; Catechols; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Enzyme Inhibitors; Extracellular Fluid; Homovanillic Acid; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Neostriatum; Pargyline; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Spectrophotometry, Ultraviolet | 2011 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2010 |
Simultaneous voltammetric determination of levodopa, carbidopa and benserazide in pharmaceuticals using multivariate calibration.
Topics: Algorithms; Benserazide; Calibration; Carbidopa; Dopamine Agents; Drug Combinations; Electrochemical Techniques; Electrodes; Excipients; Levodopa | 2010 |
Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
Topics: Antiparkinson Agents; Antithyroid Agents; Benserazide; Carbimazole; Drug Combinations; Female; Graves Disease; Heart Rate; Humans; Hyperthyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Thyroxine | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Partial Agonism; Dyskinesia, Drug-Induced; Hyperkinesis; Levodopa; Male; Microdialysis; Motor Activity; Oxazepines; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Analysis of differences between physiological and pathological tremor of human fingers.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Electromyography; Fingers; Humans; Isometric Contraction; Levodopa; Middle Aged; Parkinson Disease; Tremor | 2010 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
[Morphological and chemical reorganizations in parietal cortical neurons in conditions of hyperactivity of the dopaminergic system].
Topics: Animals; Benserazide; Cell Nucleus; Cytoplasm; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Neurons; Parietal Lobe; Psychomotor Agitation; Rats; Rats, Wistar | 2010 |
Parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adult; Antidotes; Antiparkinson Agents; Benserazide; Cholinesterase Inhibitors; Humans; Insecticides; Levodopa; Male; Organophosphate Poisoning; Parkinson Disease; Pralidoxime Compounds; Trihexyphenidyl | 2011 |
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |
The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Auditory Perception; Benserazide; Cohort Studies; Dopamine Agents; Female; Humans; Inhibition, Psychological; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Severity of Illness Index | 2011 |
Application of silver nanoparticles and principal component-artificial neural network models for simultaneous determination of levodopa and benserazide hydrochloride by a kinetic spectrophotometric method.
Topics: Benserazide; Calibration; Chemistry; Chlorides; Hydrogen-Ion Concentration; Kinetics; Levodopa; Metal Nanoparticles; Models, Chemical; Nanotechnology; Neural Networks, Computer; Principal Component Analysis; Silver; Software | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
Topics: Benserazide; Calibration; Chromatography, High Pressure Liquid; Humans; Levodopa; Methyldopa; Quality Control; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tablets; Tandem Mass Spectrometry | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.
Topics: Anemia; Animals; Benserazide; Cell Differentiation; Cell Lineage; Disease Models, Animal; Drug Combinations; Erythropoietin; Female; Fibroblasts; Fibrosis; Kidney; Levodopa; Mice; Mice, Transgenic; Myofibroblasts; Pregnancy | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Levodopa treatment improves functional recovery after experimental stroke.
Topics: Animals; Antiparkinson Agents; Astrocytes; Benserazide; Blotting, Western; Cell Hypoxia; Cells, Cultured; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Combinations; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Glucose; Immunohistochemistry; Infarction, Middle Cerebral Artery; Levodopa; Male; Rats; Rats, Wistar; Receptors, Dopamine; Recovery of Function; Stroke | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2012 |
Successful treatment of severe abulia with co-beneldopa.
Topics: Benserazide; Cranial Fossa, Posterior; Dopamine Agents; Drug Combinations; Female; Humans; Hydrocephalus; Levodopa; Meningeal Neoplasms; Meningioma; Middle Aged; Psychomotor Disorders; Speech Disorders | 2011 |
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Levodopa; Male; Microinjections; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2012 |
Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Behavior; Benserazide; Consanguinity; Developmental Disabilities; Dopamine Agents; Drug Combinations; Eye Movements; Female; Humans; Infant; Levodopa; Movement Disorders; Muscle Hypotonia; Nervous System Diseases; Neurotransmitter Agents; Phenylketonurias; Treatment Outcome | 2012 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Benserazide; Blood-Brain Barrier; Capillaries; Cerebrovascular Circulation; Dyskinesias; Female; Glucose; Immunohistochemistry; Intermediate Filament Proteins; Levodopa; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Sprague-Dawley; Sympatholytics; Tyrosine 3-Monooxygenase | 2012 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; GTP-Binding Protein alpha Subunits; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement; Mutation; Oxidopamine; Psychomotor Performance; Receptors, AMPA; Signal Transduction; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Carriers; Drug Delivery Systems; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Scanning; Mitogen-Activated Protein Kinase Kinases; Nanomedicine; Nanoparticles; Particle Size; Phosphorylation; Proto-Oncogene Proteins c-fos; Rats; tau Proteins | 2012 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline | 2012 |
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution | 2012 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
Topics: Antiparkinson Agents; Benserazide; Copper; Drug Combinations; Iron; Levodopa; Mass Spectrometry; Spectrophotometry, Ultraviolet; Zinc | 2013 |
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Injections, Intraventricular; Levodopa; Potassium; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Signal Transduction | 2013 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine Agonists; Food, Formulated; Levodopa; Magnesium; Magnesium Deficiency; Male; Mice; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
Topics: Benserazide; Capsules; Color; Dopamine Agents; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Quality Control; Tablets; Therapeutic Equivalency | 2013 |
Adjunctive Madopar for ultrarefractory epilepsy? Preliminary observations.
Topics: Adult; Anticonvulsants; Benserazide; Brain Injuries; Drug Combinations; Enzyme Inhibitors; Epilepsy; Follow-Up Studies; Humans; Intellectual Disability; Lennox Gastaut Syndrome; Levodopa; Male; Spasms, Infantile | 2013 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological | 2013 |
Reduction in Parkinson's disease therapy improved punding but not feeling of presence.
Topics: Antiparkinson Agents; Benserazide; Compulsive Behavior; Emotions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2013 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease | 2014 |
Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzopyrans; Corpus Striatum; Dependovirus; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Genetic Vectors; Green Fluorescent Proteins; Immunohistochemistry; Levodopa; Mastication; Motor Activity; Neurons; Oxazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Transfection | 2014 |
Reversal of stroke induced lymphocytopenia by levodopa/benserazide treatment.
Topics: Animals; Benserazide; Drug Combinations; Levodopa; Lymphopenia; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Remission Induction; Single-Blind Method; Stroke; Treatment Outcome | 2014 |
Reduction of rat brain CD8+ T-cells by levodopa/benserazide treatment after experimental stroke.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; CD8-Positive T-Lymphocytes; Chemokine CXCL1; Infarction, Middle Cerebral Artery; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukins; Levodopa; Male; Rats; Rats, Sprague-Dawley | 2014 |
Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Topics: 3,4-Dihydroxyphenylacetic Acid; Allylbenzene Derivatives; Animals; Anisoles; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopamine; Dopamine Agents; Drug Combinations; Drug Interactions; Homovanillic Acid; Levodopa; Male; Monoamine Oxidase; Rats; Serotonin; Tyrosine 3-Monooxygenase | 2014 |
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Muscle Tonus; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Polysomnography; Recombinant Fusion Proteins; Sleep Deprivation; Sleep Disorders, Intrinsic; Sleep, REM; Urotensins; Wakefulness | 2014 |
Follow-up management of refractory continuous positive airway pressure therapy: emergent periodic limb movements in sleep.
Topics: Benserazide; Carbamazepine; Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Polysomnography; Sleep Apnea, Obstructive | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain--influence of levodopa treatment.
Topics: Animals; Antigen-Presenting Cells; Benserazide; Brain; Cytokines; Disease Models, Animal; Dopamine Agents; Drug Combinations; Flow Cytometry; Functional Laterality; Histocompatibility Antigens Class II; Infarction, Middle Cerebral Artery; Levodopa; Macrophages; Male; Microglia; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors | 2015 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.
Topics: Animals; Antioxidants; Benserazide; Betaine; Brain; Dopamine; Dopamine Agents; Drug Combinations; Glutathione; Glutathione Peroxidase; Humans; Hyperhomocysteinemia; Levodopa; Lipid Peroxidation; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2015 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Random Allocation | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Mice; Parkinson Disease; Receptors, Neurotransmitter; Severity of Illness Index; Time Factors | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2016 |
Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Topics: Animals; Benserazide; Catechols; Cell Line; Corpus Striatum; Dopamine; Drugs, Chinese Herbal; Hydrazines; Levodopa; Male; Medicine, East Asian Traditional; Nitriles; Oxidopamine; Pargyline; Rats; Rats, Wistar | 2016 |
Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Hydrazines; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Oxadiazoles; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Topics: Animals; Benserazide; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Neostriatum; Nortropanes; Parkinson Disease; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Tomography, X-Ray Computed; Tyrosine 3-Monooxygenase | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
[Benefits of the combination of mucuna, green tea and levodopa/benserazide in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Mucuna; Parkinson Disease; Tea | 2016 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Potentials; Fourier Analysis; Levodopa; Locomotion; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar; Time Factors | 2016 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2017 |
Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Benserazide; Case-Control Studies; Cross-Sectional Studies; Dopamine; Dopamine Agents; Drug Combinations; Female; Frail Elderly; Frailty; Geriatric Assessment; Geriatrics; Humans; Inpatients; Levodopa; Male; Parkinson Disease; Phenotype; Poland; Predictive Value of Tests; Prevalence; Severity of Illness Index | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |
Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Levodopa; Molecular Structure; Nitriles | 2017 |
Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.
Topics: Adsorption; Benserazide; Electrons; Hydrogen Bonding; Levodopa; Models, Molecular; Molecular Conformation; Nanotubes, Carbon; Parkinson Disease; Quantum Theory | 2018 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Motor Cortex; Muscle Rigidity; Muscular Atrophy, Spinal; Parkinson Disease; Positron-Emission Tomography; Tremor | 2017 |
The nature of postural tremor in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cluster Analysis; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Posture; Prevalence; Rest; Tremor | 2018 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Osmotic Demyelination Syndrome With Evolving Movement Disorders.
Topics: Acute Disease; Adult; Akinetic Mutism; Athetosis; Benserazide; Chorea; Demyelinating Diseases; Dopamine Agents; Drug Combinations; Fluid Therapy; Gastroenteritis; Humans; Hyponatremia; Levodopa; Male; Myelinolysis, Central Pontine; Parkinsonian Disorders; Saline Solution; Time Factors | 2018 |
Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms.
Topics: Benserazide; Delayed-Action Preparations; Dosage Forms; Drug Combinations; Drug Delivery Systems; Drug Liberation; Enzyme Inhibitors; Fasting; Humans; Levodopa; Postprandial Period; Pressure; Stomach | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2018 |
A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin.
Topics: Amyloid; Benserazide; Cell Line, Tumor; Cell Survival; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Protein Aggregates; Serum Albumin, Human | 2019 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; Forelimb; Gait Disorders, Neurologic; Interpersonal Relations; Levodopa; Locomotion; Male; Maze Learning; Memory Disorders; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2019 |
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Child; Consanguinity; Dopamine Agents; Drug Combinations; Epilepsy, Temporal Lobe; Exome Sequencing; Female; Humans; Hyperkinesis; Infant; Levodopa; Movement Disorders; Phosphoric Diester Hydrolases; Siblings | 2019 |
Parkinsonism Caused by Viral Encephalitis Affecting the Bilateral Substantia Nigra.
Topics: Acyclovir; Benserazide; Drug Combinations; Drug Therapy, Combination; Encephalitis, Viral; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra; Young Adult | 2019 |
Hypnic Headache with Dopaminergic Neuron Dysfunction: New Insight from a Rare Case.
Topics: Benserazide; Brain; Cocaine; Dopamine Agents; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Drug Combinations; Fluorodeoxyglucose F18; Headache Disorders, Primary; Humans; Levodopa; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Putamen; Radiopharmaceuticals | 2019 |
Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benserazide; Case-Control Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Quality of Life; Sensitivity and Specificity; Sitting Position; Walking | 2019 |
Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Female; Green Fluorescent Proteins; Hippocampus; Levodopa; Maze Learning; Memory; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; MPTP Poisoning; Neurogenesis; Random Allocation; Sedentary Behavior | 2019 |
Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Capsules; Cation Exchange Resins; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Levodopa; Lipids; Male; Rats; Suspensions; Tablets, Enteric-Coated | 2019 |
Determining the Distribution of Active Pharmaceutical Ingredients in Combination Tablets Using Near IR and Low-Frequency Raman Spectroscopy Imaging.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Levodopa; Spectroscopy, Near-Infrared; Spectrum Analysis, Raman; Tablets | 2020 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sepsis; Sepsis-Associated Encephalopathy | 2020 |
Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
Topics: Aged; Antiparkinson Agents; Benserazide; Computer Simulation; Conditioning, Operant; Dopamine Agonists; Drug Combinations; Female; Humans; Learning; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Phenotype; Punishment; Reward; Tremor | 2020 |
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Benserazide; Dopamine Agents; Drug Combinations; Encephalomyelitis; Humans; Levodopa; Male; Muscle Rigidity; Myoclonus; Receptors, Glycine | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Induction of Ticlike Involuntary Movements in Rats by Striatotomy and Subsequent Neurochemical Sensitization.
Topics: Analgesics, Non-Narcotic; Animals; Benserazide; Corpus Striatum; Dopamine Agents; Double-Blind Method; Drug Combinations; Ergotamine; Female; Globus Pallidus; Levodopa; Naloxone; Prospective Studies; Rats; Rats, Wistar; Stereotaxic Techniques; Tourette Syndrome | 2021 |
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benserazide; Cognitive Dysfunction; Drug Combinations; Fever of Unknown Origin; Handwriting; Humans; Immunosuppressive Agents; Immunotherapy; Levodopa; Male; Methylprednisolone; Neuropsychological Tests; Parkinson Disease, Secondary; Tremor | 2021 |
The impact of treatment of periodic limb movements in sleep on blood pressure in patients with and without sleep apnea.
Topics: Aged; Benserazide; Blood Pressure; Dopamine Agonists; Humans; Levodopa; Middle Aged; Restless Legs Syndrome; Retrospective Studies; Sleep; Sleep Apnea Syndromes; Sleep Apnea, Obstructive | 2022 |
The effect of Madopar on absence‑like seizures in WAG/Rij rats.
Topics: Animals; Benserazide; Disease Models, Animal; Drug Combinations; Electroencephalography; Epilepsy, Absence; Levodopa; Male; Rats; Rats, Wistar; Seizures | 2022 |
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
Discovery of Two Inhibitors of the Type IV Pilus Assembly ATPase PilB as Potential Antivirulence Compounds.
Topics: Adenosine Triphosphatases; Bacterial Proteins; Benserazide; Fimbriae Proteins; Fimbriae, Bacterial; Levodopa | 2022 |
Electrochemical Sensor Based on Multi-Walled Carbon Nanotubes and N-Doped TiO
Topics: Benserazide; Electrochemical Techniques; Electrodes; Levodopa; Nanotubes, Carbon; Oxidation-Reduction | 2022 |
[Clinical and genetic characteristics of children with dopa-responsive dystonia caused by tyrosine hydroxylase gene variations].
Topics: Benserazide; Dystonia; Female; Humans; Hypokinesia; Infant; Levodopa; Male; Muscle Hypotonia; Retrospective Studies; Tyrosine 3-Monooxygenase | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease | 2023 |